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Summary
The cell surface molecule LEU-8 has been reported to identify the 
human homologue of the MEL-14 lymph node homing receptor by sequence 
comparison of the two antigens (Camerini et al.y 1989). However, it has 
never been directly tested for its ability to specifically detect lymphocytes which 
home to human lymph nodes. This study was designed to generate 
monoclonal antibodies against the nodal lymphocytes in order to identify marker 
unique to the node, and to compare this with the homing function suggested for 
the LEU-8 marker. At the same time, LEU-8 was tested for a homing 
function in humans by comparison of its relative expression in lymph node and 
peripheral blood of breast cancer patients using two-colour flow cytometry.
This work also set out to assess local immunological responses in the 
nodes and peripheral blood, and to analyse the expression in the nodes and its 
relationship to the expression pattern of the human lymphocyte homing receptor 
CD44.
The antigens of human nodal lymphocytes identified by three 
monoclonal antibodies were not unique to the node, and no specific homing 
molecule was identified despite a logical strategy. The monoclonal antibodies 
produced were to B cell antigens that were unlikely to be MHC Class I or 
immunoglobulin. B cells were not quantitatively dominant in the human 
lymph node but were highly immunodominant.
The data showed that CD3+ or CD 19+ cells did not express LEU-8 
preferentially in the human lymph node, and indeed the latter showed a 
preference for location in the blood. LEU-8 was irrelevant to T lymphocyte 
homing and a negative indicator of B cell homing. Taken together, there was
31
no functional evidence from this study that the LEU-8 cDNA homologous to 
mouse MEL-14 antigen does indeed encode a human lymph node homing 
receptor.
In the local lymph nodes of breast cancer patients, the activation marker 
IL-2 receptor (Tac) was present on a higher proportion on CD4+ than CD8+ 
cells in two axillary lymph nodes (near and far from their draining tissue) and 
peripheral blood. In contrast, the percentage of CD8+ T cells bearing the 
activation marker HLA DR was higher than the percentage of HLA DR 
expressing CD4+ T cells in all cases.
CD44 was preferentially located in the human lymph node, but did not 
show significance difference between lymph node and peripheral blood such 
that was difficult to deduce homing. This study suggest that CD44 might be a 
homing receptor in humans, but more data is required for statistical validity. 
More interestingly both CD44 and LEU-8 were present on primary and 
metastatic tumour cells, and may therefore have prognostic and diagnostic 
potential in primary and metastatic breast carcinomas.
CHAPTER 1 
INTRODUCTION
33
1.1 The Human Immune Response
1.1.1 TandB Cells
The function of the immune response in humans is to employ specific 
cells and molecules to protect the host from foreign substances and itself. 
This response involves multiple cellular interactions mediated by soluble growth 
and differentiation factors. The immune specificity is determined by T and B 
lymphocytes. Extracellular bacteria are susceptible to attack by antibody 
produced from B cells in conjunction with complement or phagocytes, while 
intracellular bacteria or viruses require an intact T cell system to ensure effective 
eradiction.
1.1.1.1 B Cells (CD19)
B lymphocytes are involved in the humoral immune response, which is 
the main defence mechanism against extracellular microbes. A substantial 
repertoire of antibodies or immunoglobulins in the immune system is provided 
by B lymphocytes. This specificity and diversity of the immune response is 
based on clonal selection hypothesis (Burnet, 1959). The diversity of 
antigen-binding V regions of immunoglobulin (Ig) molecules for an antigen is 
made up by combination of domains in the variable (V) regions of the heavy 
(H) and light (L). The development of B cells into mature antibody secreting 
cells can be divided into two stages, antigen independent and dependent steps 
(Figure 1.1). All B lymphocytes are derived from a stem cell in the bone 
marrow that does not produce immunoglobulin, and also gives rise to the 
erythroid and myeloid lineages of blood cells and to T lymphocytes (Smith et 
al., 1991). B lymphocytes are continuously generated throughout life 
because of the self-renewing capacity of stem cells. Antigen-sensitive B cells 
occur in the circulation and secondary organs, such as spleen and lymph nodes.
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In pre-B lymphocytes, the Ig gene product containing p. heavy chain composed 
of variable and constant (C) regions is synthesised in the cytoplasm. The 
immature B cell expresses a complete heavy and light chain, either k  or X, and 
then produces assembled IgM molecules on the cell surface. After having 
acquired a complete Ig, B cells migrate out of bone marrow and continue to 
mature in the peripheral circulation and lymphoid tissues. Stimulation by 
antigen through the surface Ig molecule activates the B lymphocytes to 
proliferate and mature. Mature B cells co-express \i and 5 heavy chains in 
association with the original k  or X light chain and express both monomer IgM 
and IgD. These mature B cells can respond to T-independent antigens by 
proliferation and maturation to IgM-secreting cells without Ig class switching or 
hypermutation of the Ig V gene regions. Alternatively, they can respond to T- 
dependent antigens, again by proliferation and maturation, first to IgM 
secretion, then to surface expression, and later to secretion of other classes of 
Ig. T cell-dependent responses induce not only class switching but also 
hypermutation in the V region segments of Ig H and L chain genes. This 
reaction occurs in secondary lymphoid organs in germinal centers (Rolink and 
Melchers, 1991).
The activated B cells differentiate into antibody secreting cells, which 
begin to express Ig heavy chain classes (e.g. y, a , or £) other than p. and 8, 
undergoing heavy chain class (isotype) swiching (Tonegawa, 1983), and 
memory cells, which may not secrete antibody but have potential to participate 
in the secondary antibody response by secondary stimulation from the same 
antigen.
Figure 1.1 B cell development
Stage I : Ag-independent, Stage I I : Ag-dependent
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Surface Ig on B cells can couple to independent pathways of G-protein 
regulated PLC- and PTK-mediated PLC-activation and/or G-protein-dependent 
PTK-mediated PLC activation (Harnett and Rigley, 1992; Cushley and Harnett, 
1993) (Figure 1.2). PLC mediates hydrolysis of phosphatidylinositol 
bisphosphate(PIP2) to generate the intracellular second messengers inositol 
trisphosphate (IP3) and diacylglycerol (DAG) (Bijsterbosch et al., 1986). 
The activation of PTK leads to the tyrosyl-phosphorylation of target proteins 
(Campbell and Sefton, 1990). The identity of the PTK(s) is likely to be one 
or more of the src-related PTKs, blk, lyn, and fyn recently shown to be 
associated with the mlg receptors (Yamanishi et al., 1991; Burkhardt et al., 
1991). The antigen receptors are coupled to various PLC isoforms via G- 
proteins and/or PTKs depending on their state of activation or differentiation.
Plasma
G-Protein
PI-3KPIP2 PIP2BCR
DflG DRG
I P 3
P L C - Y i
PLC- p
PKC
2+
PTK
PKC
Cellular
Activation
Figure 1.2 Signalling pathways of antigen receptor coupling of interactive G- 
protein/PTK mediation of B cell signalling
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1.1.1.2 T Cells (CD3)
T ceils are involved in cellular immunity. They recognise and respond 
to cell surface-associated but not soluble antigens, and cause the lysis of 
infected cells. T lymphocytes are derived from a common lymphoid- 
committed stem cell (CD34), which migrates from the bone marrow to colonize 
the thymus. Within the thymic microenvironment, T cells differentiate to 
become mature, functional cells which are responsive to antigen in the context 
of major histocompatibility complex (MHC) proteins (Section 1.1.1.5). The 
specificity for antigen is determined by the T-cell receptor (TCR) expressed on 
the surface of T lymphocytes.
1.1.1.2.1 CD4 and CD8
The majority of T lymphocytes can be divided phenotypically into two 
subsets, CD4 and CD8 which are encoded by genes which are cloned and 
characterised. One consists of cells, helper (Th), expressing the CD4 surface 
marker and the other consists of cytotoxic cells (Tc), expressing CD8 on their 
cell surface (Figure 1.3). CD4 is a monomer of 55-67 kDa with a highly 
conserved cytoplasmic domain (Maddon et al., 1985). CD8 is a 32 kDa 
structure that forms homomultimers or heterodimers with CD1 or MHC class I 
(Snow et al., 1985; Blue et al., 1988). This phenotypic distinction has
generally been correlated with a fundamental functional difference, namely that
CD4+ T lymphocytes apparently perform "helper" functions and exhibit an 
antigen response restricted to MHC class II molecules, whereas CD8+ T cells 
are cytotoxic to antigen-bearing target cells and usually are MHC class I- 
restricted (Glasebrook et al., 1983). The CD4 and CD8 antigens are 
glycoproteins expressed on reciprocal subsets of T cells within the peripheral 
blood compartment and have also been implicated in the regulation of T-cell
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growth (Reinherz et al., 1983). Both antigens are members of the 
immunoglobulin gene superfamily (Williams and Barclay, 1988). CD4 and 
CD8 function to increase the avidity of the T cell for antigen by binding to MHC 
class II and I antigens, respectively. This has led to the suggestion that CD4 
and CD8 may generate intracellular signals (Section 1.1.1.2.3) either 
independently and/or in conjunction with the TCR/CD3 complex. CD4+ 
helper T lymphocytes appear to perform most functions via the action of 
secreted lymphokines (Prystowsky et al., 1982). These factors modify the 
activity of the T cells that produce them in an autocrine fashion, as well as 
modulating responses of other cells in a paracrine fashion. CD8+ cytotoxic T 
lymphocytes also secrete some lymphokines in response to antigenic 
stimulation, but the range is generally comparatively restricted. CD4 and CD8 
have influence in the selection of TCR repertoire in the thymus (Von Boehmer 
et al., 1989). The T-cell receptor complex (TCR/CD3) is therefore clearly 
linked to the specific recognition of MHC and antigenic determinants and the 
subsequent activation of T cells. Interactions between TCR/CD3 and these T- 
cell antigens control the expansion of certain T-cell subsets with specific 
immune functions such as help, cytotoxicity and suppression.
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Figure 1.3 Function of the CD4 and CD8 molecules.
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1.1.1.2.2 Regulation of T cell activation
The growth of many cells is regulated by intracellular molecules and
integral membrane receptors which possess protein-tyrosine activity (Hunter
and Cooper, 1985). T cell activation is a series of intracellular events,
beginning with second messenger generation and ending with the development
of effector functions and T cell proliferation. Current models of lymphocyte
activation involve the relative roles of guanine nucleotide binding proteins (G-
proteins) and src-related protein tyrosine kinases (PTKs) in antigen receptor-
mediated signalling (Harnett and Rigley, 1992) followed by the release of
intracellular Ca^+ and the activation of protein kinase C (Weiss et al., 1986).
Protein kinases have different kinds and each type may be responsible for
phosphorylating different transcriptional regulatory proteins. Protein-tyrosine
kinases are known to a effect on regulation of cell growth. At present the
model of T cell activation is that, following ligation of the T cell antigen
receptor, src - related PTKs - mediate regulation of PLC activation (Figure 1.4).
The T cell receptor (TCR) is coupled to phospholipase C (PLC)-mediated 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two
potent intracellular second messengers, inositol 1,4,5-triphosphate (IP3) and
diacylglycerol (DAG) (Nishizuchi, 1988). IP3 can diffuse into the cytosol 
contributing to the release of Ca^+, mostly from the endoplasmic reticulum. 
DAG, on the other hand, can bind and activate protein-kinase C (PKC), thereby 
initiating the phosphorylation of numerous substrates at serine and threonine 
residues. TCR can also couple to ras activation (Downward et al., 1992) and 
the CD4/CD8 molecules which form a signalling complex, not only with the 
PTK lek (Section 1.1.1.2.3) but also with a novel 32 kDa GTP-binding protein 
(Telfer et al., 1991). G protein regulation of intrinsic PTK growth factor is 
associated with T cells that are differentially coupled to inositol phosphate 
generation, depending on their state of activation or maturation.
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1.1.1.2.3 The function of CD4/CD8 in human T cell activation
The primary pathway of clonal expansion occurs by means of antigen 
recognition by the T cell receptor (TCR)/CD3 complex (Section 1.1.1.2.4). 
Several accessory interactions involving CD4:MHC class II, CD8:MHC class I 
and LFA-1:ICAM-1 (Section 1.3) synergize with the TCR/CD3 complex in this 
response to foreign antigen. The CD4 and CD8 antigens abrogate or 
potentiate activation depending on their proximity to the TCR/CD3 complex. 
The effects of proximity might be also correlated with the tyrosine 
phosphorylation of the CD3 £ chain (Samelson et al., 1985). Cell adhesion 
and conjugate formation are important consequences of these binding events. 
These accessory interactions may also trigger intracellular signals that modify 
antigen-induced proliferation via the TCR/CD3 complex. Significantly, 
several structures (CD4, CD8 and CD45) define subsets of T cells with distinct 
functional programmes. CD4, CD8 and CD45 in conjunction with the 
TCR/CD3 complex appears to play a major role in regulating the activation and 
effector functions of distinct T-cell subsets. The leukocyte common antigen, 
CD45 has a variable ectodomain (Thomas 1989) and a constant cytoplasmic 
domain consisting of two tyrosine-specific phosphatase domains in tandem 
(Charbonneau et al., 1988; Tonks et al., 1989). CD45 has tyrosine-specific 
phosphatase activity (Tonks et al., 1989) which plays a role in the process of 
signal transduction in the T-cell activation appearing to involve tyrosine kinases. 
Different CD45 isoforms associate differentially with the T cell receptor and 
with the coreceptors CD4 and CD8. CD45 is a tyrosine-specific phosphatase 
that occurs in various distinct isoforms on T cells with different functions or 
activation requirements. On naive T cells expressing the ABC isoforms, 
CD4, CD45, and the TCR all migrate independently on the T-cell surface 
(Dianzani et al., 1992). On memory T cells expressing the null isoform of 
CD45, CD4, TCR and CD45 RO are all associated on the T-cell surface 
(Volarevic et al., 1990). Finally, on Th2 cloned lines, an undefined low
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molecular weight CD45 isoform binds to CD4 but this complex does not bind 
the TCR. T-cell activation occurs optimally when the TCR, CD4, and CD45 
are brought together on the T-cell surface. This may reflect the interplay 
between the TCR and CD4 associated tyrosine kinases and the tyrosine 
phosphatase activity found on the cytoplasmic domains of CD45. CD4 and 
CD8 function is to associate with the T cell-specific protein-tyrosine kinase 
p56^. Engagement of the CD4/CD8 receptor by MHC antigens in 
conjunction with the TCR/CD3 complex would be expected to stimulate p 5 6 ^  
activity (Figure 1.5). The lck binds to a distinct sequence in the cytoplasmic 
tail of CD4 and CD8 (Shaw et al.t 1990; Turner et al.y 1990). The lck 
molecule contains a conserved carboxyl terminus, and the tyrosine at amino acid 
residue 505 is a regulatory tyrosine. The lck function is probably regulated 
through the phosphorylation and dephosphorylation of this regulatory T y r^ . 
CD4 leads to increased levels of phosphorylation lck as well as increased kinase 
activity, while dephosphorylation of tyrosine 505 activates kinase activity in lck 
(Luo and Sefton, 1990). The coreceptor CD4 and CD8 participate in 
transmembrane signal transduction that correlate with tyrosine phosphorylation 
of the TCR £ chain via p56^ . The importance of this event in T-cell 
activation is not yet known. The CD4/CD8:p56^complex may constitute the 
underlying molecular basis of the CD4 and CD8 function and their ability to 
synergize with the TCR/CD3 complex. Potentially important targets of the 
CD4- and CD8-associated p 5 6 ^  are the CD3 subunits of the TCR/CD3 
complex. p 5 6 ^  could provide the molecular basis for an interaction between 
CD4/CD8 and the TCR/CD3 complex in the recognition of foreign antigen. 
The CD3 y, 8 and e chains are also phosphorylated at tyrosine residues by the 
0 )4 /0 3 8 ^ 5 6 ^  complex. The net result of CD3 phosphorylation may be to 
alter the inter-molecular associations within the TCR/CD3 complex leading to a 
cascade of events linked to DNA replication. Alternatively, CD3 could act to 
regulate the activity of the kinase and/or alter its substrate specificity. Surface
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expression of CD4 antigen does not prevent the association of p 5 6 ^  with the 
CD8 antigen, and vice versa.
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Figure 1.5 CD4/CD8:p56^ complex and its intracellular association with 
CD45 and the TCR/CD3 receptor complex in T-cell activation. T cell receptor 
polypeptides showing the contribution of variable(V), diversity(D), joining(J) 
and constant(C) gene segments. N represents areas of N region addition.
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The association of p56fck\vith both antigens when expressed on the same cell is 
consistent with the notion that both receptors could utilize the kinase in signals 
driving the differentiation of CD3±CD4+ CD8+ thymocytes to a more mature 
CD3+CD4+CD8- or CD3+CD4-CD8+phenotype.
1.1.1.2.4 The T cell receptor and the CD3 complex
Antigen-induced stimulation and subsequent events are directly linked to 
an interaction with the TCR/CD3 receptor complex. Subsequent biochemical 
analysis showed that the human antigen receptor is comprised of two subunits 
at 49 (a) and 42 kDa (b) that are disulphide linked to form a heterodimer of 80- 
90 kDa (Acuto et al., 1983), and specifically bind antagonistic peptides 
presented by MHC molecules (Section 1.1.1.5) and a complex termed "CD3". 
Genetic analysis further revealed a close structural relationship between 
immunoglobulin and the T-cell receptor with each subunit being encoded by 
germline V, D, J segments which undergo rearrangement during T-cell 
differentiation (Hendrick et al., 1984; Yanagi et al., 1984). Transfection of 
cells with defined a  and p chain cDNAs has revealed that the receptor can 
recognize both antigen and MHC specificities (Yague et al., 1985). Other T- 
cell receptors termed y/5 and yy have been defined biochemically (Brenner et al., 
1987; Bank et al., 1987; Borst et al., 1987), and genetically (Saito et al., 1984; 
Chien et al., 1987). The various types of antigen receptors (a/p, y/8 and yy) 
form multimeric complexes with the various chains of the CD3 complex. The 
same assortment of CD3 chains are associated with the a/p and y/8 
heterodimers which are closely related in regions proximal to the plasma 
membrane and in their cytoplasmic tails (Krissansen et al., 1986).
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The human T cell antigen receptor
The T cell receptor genes are split in the germline DNA into a number of 
gene segments comprising V, D, J, and C segments. These gene segments 
recombine in a developing T cell to produce a contiguous V(D)J exon. The a  
chain gene is located on chromosome 14 at 14ql 1 (Caccia et al., 1985; Collins 
et al., 1985) and the 6 TCR locus lies between Va and Ja. The TCR p chain 
gene complex spans around 600 kb on chromosome 7 (Lai et al., 1988) and 
incorporates some 57 Vp gene segments (Robinson, 1991). The y-chain 
locus gene is localized to the short arm of chromosome 7 (Murre et al., 1986). 
8 of 14 Vy segments are functional, located upstream of two sets of J8 
segments, each with a constant region complex. Cyl is composed of three 
exons: the first encodes the extracellular domain, the second codes for a 
connecting region, and the final exon encodes the transmembrane domain and 
cytoplasmic tail. The human 8 chain gene complex lies within the chain 
complex, between the Va and Ja segments (Hata et al., 1987; Chien et al., 
1987). The y gene is rearranged and expressed at an early stage in T cell 
development and forms either disulphide-linked or non-disulphide-linked 
dimers with the so-called 8 protein. The four distinct T-cell antigen receptor 
polypeptides (a, P, y, 8) form two heterodimers (a/p and y/8). The a/p  
heterodimer plays the part of recognition of antigenic peptides combining the 
MHC molecules, while the y/8 TCR for antigen is expressed in only 1-2% of T 
lymphocytes in systemic lymphoid organs or blood of men. This minor 
fraction mainly consists of cells that carry the CD3 antigen, termed CDS^CIM" 
CD8" or double-negative. Alam et al., (1992) reported that the majority of 
cells in both PBL and LNL were "double negative" and in TILs, the CD8 
marker was consistently present on a substantial proportion of CD3+ y/8+ cells 
in breast cancer patients. In humans there is no evidence of y/8 T cells 
preferentially homing or localizating in epithelia (Itohara et al., 1990).
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The CD3 molecule
The CD3 molecule was initially identified as a cell surface antigen 
present on mature human thymocytes and peripheral T cells by T-cell specific 
monoclonal antibodies (Reinherz et a l, 1979). CD3 is actually a complex of 
5 distinct polypeptides termed y, 5, e, £ and r| identified in noncovalent 
association with the TCR a/p. Molecular weights of these proteins range in 
size between 16,000 and Mr 28,000. Each of y, 6 and e chains shows a high 
degree of sequence similarity to the others and the genes encoding these three 
subunits are clustered in a small region of human chromosome 11 (Clevers et 
al., 1988; Gold et al., 1987; Tunnacliffe et al., 1987). The y and 6 subunits 
contain 1 to 3 extracellular N-glycosylated sites, while e, C, and tj are non­
glycosylated. In contrast to a/p chains, the mass of the polypeptide chains 
for each of these subunits is distributed between extracellular and cytoplasmic 
domains. The predominant form of £ is as a homodimer and 10% of t, is 
found as a heterodimer with a 22K protein, termed T| (Orloff et al., 1989). £
chain has a 9 amino acid extracellular domain and a larger cytoplasmic domain 
of 112-113 amino acids. £ chain plays a critical role in the signalling function 
of the TCR (Section 1.1.1.2.3.). When T cells are activated by antigen the £ 
chain is phosphorylated on tyrosine residues. The cytoplasmic region of £ 
chain has 7 tyrosine residues in human that are substrates for tyrosine protein 
kinases and also posses a ATP binding sequence (Weissman et al., 1988).
1.1.1.3 T and B Cell Interaction
Early experiments by Mitchison (1971) demonstrated that T dependent 
antigens are involved in the recognition mechanism between B and T cells. 
Inside the macrophages and B cells, the bacterial toxins and other foreign 
antigens in the blood are degraded, and their processed peptides are then
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transported to the surface by class II MHC molecules. Once TCR and the 
CD4 coreceptors of a pre-helper T cell are bound by the same MHC molecules 
on a presenting cell (Section 1.1.1.4.5.)* the T cell starts to divide and produces 
active helper T cells. The dynamic interaction of multiple cell surface 
receptor-coreceptor pairs is involved in both signal transduction and adhesion 
for T-cell activation.
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Figure 1.6 The response of helper T cells to antigens presented by B cells.
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These accessory molecules specifically bind other molecules (ligand) present on 
the other cell surfaces, which result in increase the strength of adhesion between 
a T cell and B cell. And they are nonpolymorphic and invariant, which 
implies that have no capacity to specifically recognize many different and 
variable ligands. The active helper T cells produce a variety of lymphokines 
including interleukin(IL)-2,3,4,5,6, and 10, granulocyte-macrophage colony 
stimulating factor (GM-CSF), tumour necrosis factor a  (TNF-a), and 
interferon-gamma (IFN-y). T cell-B cell interactions control lymphokine gene 
expression by regulating both the rate of transcription and mRNA stability 
(Fraser et a!., 1993) that further stimulate the B cells to divide and to secrete 
large amounts of their specific antibodies, which circulate freely in the blood, 
bind to the toxin and neutralise it (Boehmer and Kisielow, 1991) (Figure 1.6). 
The B lymphocyte in its resting state is little more than a nucleus surrounded by 
a thin enclosure of cytoplasm. Once a B cell meets a matching antigen, it 
develops an extended body containing polyribosomes, which make antibodies, 
and an elaborate channel system for exporting these antibodies (Nossal, 1993).
1.1.1.4 Major Histocompatibility (MHC) Antigens
The MHC class I and II molecules are highly polymorphic membrane 
glycoproteins. The alpha-beta receptors of T lymphocytes recognise antigen 
in association with the polymorphic products of the class I and II loci of the 
major histocompatibility complex. The molecular structure responsible for 
antigen presentation was revealed by resolution of the crystal analysis of the 
human class I molecule, HLA-A2 (Bjorkman et al., 1987). The specificity of 
TCR recognition depends on both polymorphic residues in the antigen-binding 
groove and the primary sequence of the bound antigen-derived peptide.
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The class I MHC a-chain is encoded on human chromosome 6 (HLA-A,B,C); 
that of the mouse are on chromosome 17 (H-2K,D,L) (Klein, 1986), and p2m 
is encoded by chromosomes 15 and 2, respectively. Invariant chain linked to 
the class II MHC molecule processing is encoded by human chromosome 5 and 
mouse chromosome 18. The human class II molecules are HLA-DR DQ, DP 
and the mouse are I-A and I-E. Each species has dozens of MHC loci, some 
of which contain pseudogenes. Klein (1979) distinguished two classes of 
MHC genes, class I and II, a distinction that well anticipated the different 
physiological function of the respective gene products.
1.1.1.4.1 Function of MHC
The function of MHC molecules is to collect peptide fragments of intact 
proteins inside the cell and transport them to the cell surface, where they can be 
surveyed by the T cells. The interaction between T-cell receptor(TCR), MHC 
molecule and the peptide presented by the MHC molecule is central to the 
cellular immune system of self/nonself discrimination. That is, MHC 
molecules function as the targets for immunologic rejection of transplants. 
Recognition of the appropriate peptide-MHC complex by the antigen specific 
receptor of T lymphocytes leads to cell proliferation and a cascade of cellular 
immune responses. The optimal peptide length for binding is between 8 and 
12 amino acids with the central 5-7 residues contributing the majority of the 
specific contacts.
1.1.1.4.2 The structure of Class I MHC
MHC class I molecules consist of a polymorphic integral membrane 
glycoprotein heavy chain of about 46 kDa and the light chain, noncovalently associated
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Figure 1.7 The structure of the class I MHC molecule and peptide receptor
with a 12 kDa soluble subunit, p2-microglobulin (p2m) (Bjorkman and 
Parham, 1990) (Figure 1.7). The heavy chain consists of three extracellular 
domains - the membrane distal, peptide binding region formed by the intimate
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association of the a l  and a2  domains, and the membrane proximal, CD8- 
binding portion termed a3  (Germain and Margulies, 1993) linked with a 
cytoplasmic tail at the carboxyl terminus. Class I MHC heavy chains possess 
separate exons that each encode a distinct domain of the protein. p2m is a 
single, compact immunoglobulin-like domain. p2m makes contact not only 
with the immunoglobulin-like a3 domain, but also with the p sheet floor of the 
a l a 2  peptide binding region. The a l a 2  domain unit forms a peptide 
binding groove, as revealed by X-ray crystallography by Bjorkman and 
colleagues in 1987. The groove is bordered by two a-helices; the floor is a 
P-pleated sheet containing eight strands. Both amino and carboxyl termini of 
the peptide are tightly bound via H-bonds by conserved residues ( Rammensee 
et al., 1993). The peptide backbone can bend more or less, to accommodate a 
different number of amino acids between the fixed MHC sites binding peptide 
amino and carboxyl termini as recently visualised by X-ray crystallography 
(Guo et al., 1992) depending on for many class I molecules, such as HLA- 
A68, HLA-B27 and HLA-A2.
1.1.1.4.3 The structure of Class II MHC
Class II molecules are heterodimers composed of a 33-35 kDa a-chain 
and a 25-29 kDa p chain. Class II HLA is polymorphic in the human 
population and different types selectively bind different sets of peptides (Chicz 
et al., 1993) that may be responsible for variations in the immune response of 
different individuals to different antigens (Todd et al., 1988). The Class II 
human leukocyte antigens(HLA) are cell surface a p  heterodimeric (Mr 
-60,000) integral membrane proteins forming a groove that is similar to that of 
the class I HLA molecule (Brown et al., 1988). The a2-and p2-domains 
have predicted homology to immunoglobulin domains. A structural
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difference between class I and II is that in class II the ends of the groove appear 
to be open to allow overhanging of both amino acid and carboxyl termini of 
bound peptides. The length of 12-20 amino acid peptides is predicted for 
clsss II MHC molecule based on primary sequence (Brown et al., 1988). 
Each dimer consists of one a  and one (3 chain in noncovalent association 
(Figure 1.8).
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Figure 1.8 The structure of the class II MHC molecule and peptide receptor
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The intron-exon organization of genes encoding class II a  and p chains 
corresponds to functional domains in the protein molecule as with class I 
(Germain and Margulies, 1993). Recent X-ray crystallography work has 
shown that a parallel dimer of the class n  HLA-DR1 ap  heterodimers suggests 
the capacity of class II HLA dimerization which could lead to an increased 
affinity for the CD4 coreceptor and to initiate the cytoplasmic signalling events 
in T-cell activation (Brown et al., 1993).
1.1. 1.4.4 Class I MHC antigen presentation
Cytosolic and nuclear proteins are degraded by large ATP-dependent 
proteosomes, and the resulting peptides are then translocated to the lumen of the 
endoplasmic reticulum (ER) membrane by a heterodimeric peptide transporter 
consisting of two multimembrane spanning proteins, TAPI and TAP2. The 
peptides may be further trimmed in the lumen of the ER to proper class I 
binding peptides of restricted length (8~11 amino acids) (Falk et al., 1991). 
At the same time MHC class I heavy (H) chain and the light chain, P2m, are 
synthesized in the ER and assemble, with the help of accessory molecules like 
p88 (88 kDa ER protein) (Degen et al., 1992) that may participate in the correct 
folding of class I molecules, to a stable class I MHC heterotrimer (H chain, 
p2m and peptide) . The resulting class I heterotrimer is then transported 
through the Golgi apparatus and the trans-Golgi reticulum (TGR) to the cell 
surface after release from the ER (Neefjes and Ploegh, 1988) (Figure 1.9). 
The rate of intracellular transport and of assembly of class I molecules shows 
allele - specific differences (Degen and Williams, 1991).
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1.1.1.4.5 Class II MHC Antigen Presentation
Class II MHC molecules generally present peptides derived from 
extracellular or surface proteins, in contrast to the antigen presentation of 
intracellular synthesised proteins by class I MHC molecules. These 
synthesized MHC class II molecules in the ER bind to an invariant chain which 
induces efficient transport of class II molecules from the ER (Anderson and 
Miller. 1992) (Figure 1.10). Invariant chain is a glycoprotein (31-43 kDa) 
composed of an extracellular carboxyl-terminus, a single transmembrane 
domain (-26 amino acids), and an amino-terminal cytoplasmic tail. The class 
II presentable peptides are generated by enzymes, cathepsin D (Van Noort et 
al., 1991) as well as cathepsin E (Bennett et al., 1992) which unfold antigens 
reducing disulfide bonds. Truncation of the cytoplasmic tail of the invariant 
chain by proteases (Blum and Cresswell, 1988) results in transport of the class 
II ap-dimer associated with the truncated invariant chain to the cell surface 
(Roche et al., 1992). The site of generation of presentable antigen for class II 
molecules is the lysosome (Harding et al., 1991), so class II molecules can bind 
peptide in lysosomal structures (Peters et al.y 1991). MHC class II molecules 
are transported after release of invariant chain from the endosomal pathway to 
the cell surface. Soluble protein internalized by binding to surface Ig or to a 
soluble antibody-antigen complex to Fc receptors result in more efficient 
presentation of this antigen to CD4+ T cells (Lanzavecchia, 1988). The 
antibody can influence the degradation of bound antigen by protecting certain 
protease-sensitive sites (Davidson and Watts, 1989).
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1.1.2 LYMPHOKINES
1.1.2.1 The Function of Lymphokines in Lymphocytes
Cytokines, as protein hormones, play a vital role in response to viral 
infection (as interferons), inflammation and immunity (as monokines and 
lymphokines) and hemopoiesis (as colony stimulating factors, CSFs) (Arai et 
al., 1990). Cytokines produced by macrophage and endothelial cells are 
involved in the establishment of innate (or natural) immunity, whereas 
cytokines produced by activated T cells are the responsible for acquired (or 
specific) immunity. Cytokines are produced during the effector phases of 
innate and acquired immunity and function as server to mediate and regulate 
immune and inflammatory responses. Lymphokines are soluble protein 
mediators produced by activated T lymphocytes which participate in the 
regulation of activation and immune response of lymphocytes. These proteins 
are involved in lymphocyte activation, growth and differentiation as regulator, 
and in nonspecific inflammatory cells as activator by elicitating response to 
specific antigen recognition.
1.1.2.2 Interleukin-2
Interleukin-2 (IL-2), one of the first lymphokines to be identified 
originally called T cell growth factor (TCGF), has had a considerable impact on 
basic and clinical immunology (Rosenberg et al., 1985). IL-2, produced by
CD4+ T cells only upon activation by antigens, functions as an autocrine 
growth factor, and also acts on both CD4+ and CD8+ cells as paracrine growth 
factor. IL-2 plays a main role in the clonal expansion of activated T cells by 
interacting with the IL-2 receptor (Smith, 1988). Secreted IL-2 is a 14~17 
kDa glycoprotein (monomer) encoded by a single gene on chromosome 4 in 
humans (Abbas et al., 1991). The clonal proliferation of matured, resting T
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cells is initiated via a process of signal transduction, in which the specific 
interaction of the antigen/MHC molecule with the TCR complex triggers the 
expression of IL-2 and its homologous receptor (IL-2R) (Taniguchi and 
Minami, 1993). The interaction of IL-2 with IL-2R leads to signal 
transduction pathways resulting in cell proliferation (Waldmann, 1989).
1.1.2.3 The Biological Effects of IL-2
IL-2 mediates growth and differentiation of human B cells (Waldmann 
et al., 1984) as both a growth factor and a stimulus for antibody synthesis. 
EL-2 generates lymphokine activated killer cells (Grimm et al., 1982) by 
stimulation of growth of NK cells, enhancement of their cytolytic function, and 
proliferation and maturation of oligodendroglial cells (Benvenisto and Merrill, 
1986). IL-2 also stimulates T cell growth and synthesis of other T cell- 
derived cytokines such as IFN-y and lymphotoxin. In addition, IL-2 can act 
in negative regulation of cell growth, programming T cells for apoptosis 
following TCR stimulation (Lenardo, 1991). So EL-2 is involved in delivery 
of various signals to a wide range of cell types through the interaction with IL-2 
receptor (Minami et al., 1993).
Cancer Immunotherapy using EL-2
IL-2 administration has become an clinical trial of adoptive 
immunotherapy of cancer. The incubation of lymphocytes in IL-2 results in 
the generation of activated lymphoid cells capable of lysing autologous or 
allogenic tumour cells (Lotze eta l., 1981 ; Chang and Rosenberg, 1989), but 
not normal cells. These lymphocyte-activated killing (LAK) cells can cause 
the regression of cancer in tumour-bearing host by tumour-specific killer cells
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after selective expansion in vitro by culture in IL-2 (Rosenberg, 1989), but 
severe side effects are observed. The combination of both are more effective 
than either alone. Interferon- or tumour necrosis factor can upregulate class I 
MHC antigen expression on tumours (Houghton et al., 1984), and they may 
exert synergistic in vivo antitumour effects for successful IL-2 therapy 
(Brouckaert et al., 1986). Tumour-infiltrating lymphocytes (TTLs) appear to 
be more specific and potent for individual tumours than LAK cells (Rosenberg, 
1990; Yamaue et al., 1990) and can traffic to the tumour site. Metastasis can 
be correlated with decreased IL-2 production in vivo, and reduced IL-2 
production is more frequent in patients with a low CD4/CD8 ratio (Lissoni et 
a l , 1990).
1.1.2.4 IL-2 Receptors
The specific cell surface EL-2 receptor (IL-2R) that binds IL-2 is a true 
cytokine receptor complex, possessing three distinct polypeptides, IL-2R0C, EL- 
2Rp and IL-2RY chains (Minami et al., 1993) (Figure 1.11). The human EL- 
2R a is a 55 kDa membrane glycoprotein (p55) capable of binding IL-2, 
originally described as Tac antigen or CD25 (Robb and Greene, 1983) on 
activated T ceUs. IL-2Ra is a mature protein 251 amino acids (aa) with a 
signal peptide of 21 aa in length and also contributes to the high-affinity 
receptor (Robb, 1986). Another component is the 75 kDa IL-2Rp subunit 
(Takeshita, et al., 1989) consisting of 286 amino acids (Hatakeyama et a l , 
1989). The cytoplasmic region of IL-2Rp can be divided into three 
subregions, serine-rich, acidic and proline-rich region, based on their amino 
acid compositions. IL-2R(5 binds IL-2 with intermediate affinity (Kd=lnM) 
and IL-2Ra with low affinity (Kd=10nM), but the noncovalent complex of the 
two chains gives rise to the high-affinity receptor complex. EL-2Ry (p64) is 
involved in the formation of the functional intermediate- and high affinity IL-
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2Rs and is required for the receptor-mediated internalisation of IL-2 (Takeshita 
et a l 1992). Noncovalently associated EL-2Ra/p/y heterotrimer forms a 
high-affinity receptor for IL-2.
C I L - 2 >
IL-2RV
IL-2R
p55 P70-75
Intracellular
Signal ISignal II
Induction of c-myc geneInduction of
c-fos'c-jim  gene Cell Proliferation
Figure 1.11 A schematic diagram of the high-affinity IL-2 receptors and two 
distinct signalling pathways
1.1.2.5 Signal Transduction in the EL-2 Receptors
The acidic-rich region of IL-2Rp plays a critical role in mediating 
growth signal transduction via the T cell-specific tyrosine kinase p 5 6 ^ , a 
member of src-family PTKs, which is associated with the CD4/CD8 membrane 
proteins (Turner et al., 1990), following IL-2 stimulation (Hatekayama et al.,
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1991) that results in the increased tyrosine phosphorylation of cellular 
substrates. This pathway leads to the induction of the nuclear proto­
oncogenes, c-fos and c-jun via the activation of p21, a membrane of the signal 
transducing GTP-binding proteins (Satoh et al., 1991) in T lymphocytes 
(Cleveland et al., 1987) and B lymphocytes (Kelly et al., 1983). Another 
pathway is that the serine-rich region of IL-2R(3 leads to c-myc gene induction 
by an as yet unknown mechanism (Shibuya et al., 1992) which functions 
upstream of certain cell cycle genes (Figure 1.11).
1.1.3 SUPERANTIGENS
Two groups of superantigens have been described so far : first,
endogenous murine products (self-superantigens) that include the minor
lymphocyte stimulating (Mis) determinants, and second, bacterial products
(foreign superantigens) such as Staphylococcal enterotoxin (SE) (Herman et
al, 1990). Self- and foreign superantigens show some differences in their
ability to stimulate T cells. CD4+ and CD8+ T cells respond to Mis
determinants (Janeway et al., 1980), and proliferate in response to the SEs
(Fleischer and Schrezenmeier, 1988). Staphylococcal enterotoxin A (SEA),
one of the most potent T-cell mitogens known ranges in size from 20 to 30 kDa,
and interacts with class II MHC on antigen presenting cells and a region on the 
surface of one of the (3-pleated sheets of the Vp domains of the TCR on T cells
(Gascoigne and Ames, 1991; Pontzer et d., 1992) (Figure 1.12). Recent
experiments show that the Mis superantigen and SEA bind to at least one
common region on class II MHC antigens (Torres et al., 1993). Superantigen
expression results in T cell proliferation and, during early ontogeny, T-cell
deletion (Choi et al., 1991). Superantigens indiscriminately activate any T 
cells whose receptors include selected Vp segments. Bound T cells secrete
IL-2, resulting in abnormally high levels of the substance, and as a result,
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massive numbers of T cells. They thereby activate millions of helper T cells, 
which may subsequently die, making them unavailable to combat later 
infections. This immune depression may help counteract autoimmunity 
(Johnson etal., 1992).
T cell
Beta-chain 
Yariable(Yp) region
YD
MHC
Antigen Presenting Cell
Figure 1. 12 Schematic diagram of the trimolecular complex 
(superantigen/TCR/class II MHC)
1.2 Lymph Nodes
Most human immunological research is performed on blood which is 
readily accessible and can be sampled without surgical intervention. 
However, most of the important immunological activity occurs in specialised 
areas of the body such as the spleen, the thymus and the regional lymph nodes. 
The regional lymph nodes "drain" lymphatic fluid from areas of the body (the 
head, the chest, the gut etc.) and monitor it for the presence of foreign antigens.
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The regional lymph nodes organise the local immune response in particular 
areas of the body. They do this either by recruiting newly emerged cells with 
the appropriate binding capacity to act within their area or by allowing the 
expansion of clones of cells with the appropriate binding capacity already within 
their area.
I Interned
mammary nodes
Axillary vein
High (apical) 
axillary nodes
Axillary
nodes
Main drainageLov axillary nodes
Tumour
Figure 1. 13 Diagram of illustrating of lymphatic drainage of the breast 
cancer patient
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Lymph nodes are distributed throughout the body, but particularly large and 
numerous lymph nodes are found in the armpits (axillary lymph nodes), groin 
(inguinal lymph nodes), in front of the abdominal aorta (coeliac lymph nodes), 
in the neck (cervical lymph nodes) and in the mesentery (mesenteric lymph 
nodes) (Klein, 1990). The axillary lymph nodes are located under the arm, 
variable in accessible number between individuals and only available as fresh 
tissue in cancer patients or kidney donors. They drain the chest/breast 
lymphatic fluid but not the lungs or more deeply situated tissues (Figure 1. 13). 
The axillary lymph node is a major contributing tissue in the organisation of 
regional immune responses in the body attracting lymphocytes bearing lymph 
node homing receptors (Section 1.4.2). Responses in such nodes can be 
precisely localised with one node showing strong immune involvement while a 
neighbouring node is quiescent. Similarly, in tumour patients, one or more 
nodes may be invaded by tumour cells while neighbouring nodes remain 
tumour free. The status of these nodes is important features in assessing the 
prognosis of a breast cancer patient. Therefore these tissues will be suitable 
samples for analysis of local immune response by lymphocytes in breast cancer 
patients.
1.2.1 Structure of Lymph Nodes
Lymph nodes are small nodular aggregates of lymphoid tissue, the 
filtering stations through which lymph percolates on its way to the blood 
stream. Each lymph node is enveloped by a fibrous thin capsule which sends 
many projections by numerous afferent lymphatics, which empty the lymph into 
a subcapsular sinus (Figure 1. 14).
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Figure 1. 14 The structure of human axillary lymph node and lymphocyte 
recirculation via the high endothelial venule
1.2.2 Lymphocyte subsets in Lymph Tissue
Lymph nodes have a defined structure. T lymphocytes, mainly CD4+ 
helper cells, are largely located in the interfollicular areas of the cortex and 
paracortical areas of the medulla (Figure 1. 14). The role of these cells may 
be to help the proliferation and differentiation of the antigen - stimulated B 
lymphocytes on the germinal centres of the follicles. The lymphoid follicle 
with its germinal centre is a site of intense cell proliferation and cell death. B -
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cell follicles are found in secondary lymphoid organs throughout the body, and 
follicular B cells can take up antigen from follicular dendritic cells (FDCs) and 
process this into a form that will activate CD4+ T cells. Antigen-driven B - 
cell proliferation, somatic, positive and negative selection (Weiss et al., 1990), 
and memory and plasma cell development appear to take place within the follicle 
(Liu et al., 1992). Whitford et al. (1992) observed that the axillary lymph 
nodes are not only the major source of B cells but also the site of a large 
proportion of mature B cells with surface IgG in breast cancer patients, and 
moreover the proportion of HLA DR expressing T cells in the nodes are higher 
than those in the peripheral blood. This study also reported that CD4+ T cells 
expressing the CD25 IL-2 receptor are found to be in greater numbers than 
CD8+ T cells. Entry of lymphocytes into the node is reported to be initiated 
by a cell - cell adhesion mechanism operating between lymphocytes and High 
Endothelial Venules (HEV) within the nodes that then direct the cellular traffic.
1.2.3 Structure of HEV
HEV are found in all secondary lymphoid organs including lymph 
nodes, Peyer's patches, tonsils, adenoids, appendix, small aggregates 
associated with the mucosal surfaces of the respiratory, gastrointestinal, and 
urogenital tracts. But HEV are absent in the primary lymphoid organs (bone 
marrow and thymus) and are normally not present in nonlymphoid organs 
(Yednock and Rosen, 1989). HEV have distinctive morphological, 
ultrastructural, and biochemical characteristics that underlie their specialised 
function in lymphocyte adhesion and extravasation. High endothelial cells 
(HEC) have domed surfaces that protrude into the HEV lumen, and are cuboidal 
to columnar in height (10-12 pm) and are linked by discontinuous macular 
junctions at their apical and basal aspects. The HEV develop from flat 
endothelial venules in response to cytokines, such as y  interferon, that are
68
secreted by antigen-stimulated T cells. HEV express tissue-specific 
determinants or address signal for lymphocyte recognition. Carbohydrates 
may serve as essential recognition determinants of the HEV ligands. A 
further unusual property of HEC is their ability to synthesise and secrete a 
sulphated glycolipid, apparently in association with a nonsulphated glycoprotein 
(Andrews et al., 1983). Specific HEV ligands appear to direct selectively the 
homing of particular lymphocytes to lymphoid tissues at distinct anatomical 
sites, "vascular addressins (VA)".
1.2.4 Vascular Addressins
Vascular addressins are expressed in an organ- or tissue-selective 
manner by a cellular or extracellular element of wider distribution, and have 
functionally related counterparts expressed by the same cellular or extracellular 
element in other tissue sites. They also mark address of such cellular or 
extracellular components for the purpose of directing cell-cell interactions or 
cellular positioning in the body. Streeter et al. (1988) defined a 58-66 kDa 
endothelial cell protein antigen expressed in mucosa-associated lymphoid 
organs, such as Peyer's patches, using Mab MECA-367, whereas MECA-79 
monoclonal antibody recognises a glycoprotein of 92 kDa in peripheral lymph 
node (PLN) (Streeter et al., 1988a) in the mouse and human. This mucosal 
vascular addressin, glycoprotein is a tissue-specific endothelial cell - adhesion 
molecule for lymphocytes and regulate lymphocyte traffic into mucosal tissues 
by mediating attachment of blood - borne cells to endothelium (Nakache et al., 
1989). Other researchers designated the endothelial - leukocyte adhesion 
molecule-1 (ELAM-1) recognised by Mab HI 8/7 and H4/18, which functions 
as an induced endothelial cell-surface molecule in EL-1, TNF, lymphotoxin and 
bacterial endotoxin that can support the adhesion of blood polymorphonuclear 
leukocytes (PMN) (Bevilacqua et al., 1987). Recent works have shown that
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several independent HEV ligands for the homing receptor (L-selectin) exist, 
some of which are tightly associated with the endothelial cell surface, such as 
the -90 kDa sulphated ligands (Imai et al., 1991), or the PLN addressins 
(Streeter et al., 1988; 1988a), and the -50 kDa - ligand (Brustein et al., 1992), 
that are secreted.
1.3 Monoclonal Antibody Detection of Lymphocyte
Populations in Human Axillary Lymph Nodes
Dual - colour parameter flow cytometric analysis of cell surface markers 
shows the different antigen densities on the membranes of lymphocytes in 
normal and cancer patients. The lymphocyte subpopulations of melanoma 
tumour - draining lymph nodes (Farzad et al., 1990) and of early breast cancer 
patients in regional lymph node and peripheral blood (Morton et al., 1986) have 
been analysed according to (a) whether or not the nodes contained metastatic 
tumour, (b) their distance from the primary tumour, and (c) pathological 
staging. There was a significant increase in CD8+ T cells associated with 
Stage II (with nodal metastases) in lymph node lymphocyte (LNL) populations, 
with corresponding decrease in CD4+ T cells. The CD4/CD8 ratio in Stage II 
was less than half that of Stage I (without metastasis). Lymph nodes closest 
to the tumour in Stage I patients contained a smaller percentage of CD 19+ B 
cells. In Stage II, tumour - free nodes nearest to the tumour showed an 
increase in CD 19+ B cells. There was also no significant difference between 
Stage I and II in peripheral blood T- or B-cells. These alterations in local 
regional immunocompetent cell subsets may be essential elements in the 
metastasis of tumour to the regional nodes and in the progression of the cancer.
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1.4 Lymphocyte Homing and Adhesion Mechanisms
1.4.1 Lymphocyte Recirculation and Homing
The overall process by which the body's repertoire of 
immunocompetent lymphocytes is continuously cycled in and out of lymphoid 
organs is called "lymphocyte recirculation" (Figure 1.14). Whereas 
lymphocytes are generally thought to reside in the circulatory system, their 
protective function is more frequently required in the tissue. In consequence 
blood - bome lymphocytes move from the blood through the tissues and local 
secondary lymphoid organs such as the nodes or Peyer's patches (PP) in the 
gut, and then back to the blood via the efferent lymphatic ducts and the thoracic 
duct. On the other hand, the spleen is not supported by lymphatic vessels, 
and so migrating cells that extravasate in the spleen migrate directly back into 
the blood (i.e. intravasate). A single lymphocyte encountering a mass of 
infected cells can have little effect, but in the local node it can undergo clonal 
expansion to obtain reinforcements of the same specificity. In contrast, those 
lymphocytes which have not encountered antigen can pass through the node 
back to the blood vascular system, whereon they can enter the same or another 
lymphoid organ. This path of recirculation takes about 24 hours (Rosen, 
1989). Thus a lymphocyte which has encountered antigen must have the 
ability to express receptors which enable it to home on the node rather pass 
through it. That is, the selective migration of lymphocyte populations to
particular anatomical sites is referred as "homing". Homing mechanisms play 
a role in the maintain of specialised microenvironments, such as distinct 
complement of lymphocyte subsets and localisation in particular tissues, and are 
critical for the dispersal and targeting of naive and memory lymphocyte 
populations that are required for effective immune inspection. The 
physiology of lymphocyte homing/recirculation is largely determined by the 
differential regulation of lymphocyte adhesion and deadhesion.
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1.4.2 Homing Receptors
A number of homing receptors (Figure 1.15) have been identified by 
laboratories, as evidenced by the ability of specific antibodies to block 
lymphocyte - high endothelial cell binding in PLN or gut-associated organs 
(Table 1.1).
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Figure 1.15 Diagram of involvement of homing receptors in adhesion 
between lymphocyte and HEV, and cell migration
Table 1.1 Summary of some immunologically relevant cell surface molecules 
proposed to be involved in lymphocyte-HEV interactions based on antibody 
inhibition studies.
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Cell Surface Other MW.(kDa) 
Molecule Names Species Family Antibodies
Associated R f 
Molecules
Mel-14 DREG 56, 80 -95 
LAM-1,
LECAM-1 
LEC-CAM-1, 
Leu-8(?),TQ1 
L - Selectin
Mouse L - Selectin Mel-14 MECA-79 1 
Carbohydrate 
(sLevis* 
Determinant),
E - Selectin
Leu-8 DREG 56, 
LAM-1, 
LECAM-1 
LEC-CAM-1, 
Mel-14(?),TQ1 
L - Selectin
Human L - Selectin Leu-8 2
CD44 pgp-1, Ly-24, 85-95  
gp90Hermes
Human Proteoglycan Hermes-1,2,3 
Polyclonal „  
anti-gp90
Hyaluronate, 3 
Collagen, 
Fibronectin, 
MIP-lp 
Che mo kin
HEBFpj 80 Rat IB .2 4
HEBF ih 40,63,135: Rat A. 11 5
G H 1 30 Guinea
Pig
CT 4 6
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1. Gallatin era/., 1983; Foxall fir a/, 1992; Picker fir a/., 1991
2. Carmerini fitd/., 1989; B oven eta/., 1989; Tedder etd/., 1990
3. Jalkanen fir a/. , 1987; Toyama-Sorimachi er&I., 1993
4. Chin er*«/, 1986
5. Rasmussen era/., 1985
6. Kraal era/., 1986
Abbreviations:
LEC-CAM : Lectin-EGF-Complement-Cell-Adhesion-Molecule 
LAM : Leukocyte Adhesion Molecule 
LECAM : Leukocyte-Endothelial Cell Adhesion Molecule 
HEBF : High Endothelial Binding Factor
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1.4.2.1 MEL-14
MEL-14 is an murine monoclonal antibody which was first described as 
defining a cell surface molecule which was specific to lymphocytes which have 
the capacity to home to the nodes in the mouse (Gallatin et al., 1983). This 
MEL-14 antigen was isolated and sequenced independently (Siegelman et al., 
1989; Lasky et al., 1989). MEL-14 inhibits human lymphocyte attachment to 
PLN HEV and has no effect on human lymphocyte attachment to mouse PP 
HEV or to HEV in the human appendix. Hermes-1 (Section 1.4.2.3) and 
MEL-14 both precipitate a 90 kDa protein from the surface of human 
lymphocytes. The approximately 120 amino-terminal amino acids resemble 
the carbohydrate binding domain of a variety of Ca^+-dependent lectins 
(Drickamer, 1988), expressed at calcium concentrations of 10^ M or greater. 
This cell surface glycoprotein (gp90^®-), binding to phosphomannosyl 
residues (Yednock et al., 1987), directly bridges lymphocytes to the HEV in 
peripheral lymph node (PLN), which shows specific sugars and 
polysaccharides can block the biological activity of the isolated receptor 
(Geoffroy and Rosen, 1989). Adjacent to the lectin domain is an epidermal 
growth factor - like domain of 33 amino acids, and closest to the membrane are 
two identical repeats of 62 amino acids (Figure 1. 16). These sequence 
repeats resemble a motif found in a number of proteins, including the 
complement regulatory proteins that bind C3 and C4, and the IL-2R. MEL- 
14 antigen has ten potential N-glycosylation sites, six of which are in the 
complement - binding homology repeats. There are no clusters of serines and 
threonines, which is consistent with the lack of O - glycosylation (Reviewed by 
Coombe and Rider, 1989). Data from cloning of these antigens show that the 
structure of CD44 (Section 1.4.2.3) and the MEL-14 antigen is different. 
Siegelman et al. (1990) suggest that lymphocyte cell surface marker Ly-22 
epitope (Toda et al., 1983) is an allelic determinant on the mouse lymph node 
homing receptor resulting from a single amino acid interchange within the EGF
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domain, and this localisation of the Ly-22 have a role of participation of the 
EGF domain in the adhesion of lymphocyte to HEV. MEL-14 antigen, 
endothelial leukocyte adhesion molecule-1 (ELAM-1) and granule membrane 
protein (GMP-140), molecular weight 140 kDa, share a common organisation 
of homology units by the data from recent cloning. MEL-14 antigen adhesion 
molecule may be expressed on HEV-like vessels at sites of Bordetella pertussis 
vaccine (BPV) - induced chronic inflammation (Dawson et al., 1992).
1.4.2.2 LEU-8
The LEU-8 molecule (L-selectin, LECAM-1) is distributed on many 
kinds of leukocytes and acts as a marker of different lymphocyte subsets. 
CD4+ LEU-8" T cells show high helper activity (Kanof et al., 1987) and MHC 
class II-restricted cytolytic activity (Takada et al., 1989), whereas CD4+ LEU- 
8+ T cells show both a suppressor - inducer activity (Damle et al., 1984). 
These data show that LEU-8+ T cells in the CD4+ T cell lineage may have 
either suppressor or helper function. In addition, LEU-8+ B cells have a 
higher response to Staphylococcus aureus Cowan-I (SAC) activation than LEU- 
8'  B cells (Kansas et al., 1985). Thus the interaction of LEU-8 with its ligand 
has the effect on signal transduction during T and B cell activation and 
differentiation (Murakawa et al., 1991). Murakawa et al. (1992) suggest that
LEU-8 participates in the activation of T cells via its ability to association with 
the TCR/CD3 complex.
This cell surface molecule recognised by the monoclonal antibody LEU- 
8 (as well as TQ1, LAM-1, DREG Mab) (Gallatin et al., 1983; Lasky et al., 
1989; Siegelman et al., 1989; Kishimoto et al., 1990) has been reported to 
identify the human homologue of the MEL-14 lymph node homing receptor by 
sequence comparison of the two antigens (Camerini et al., 1989; Tedder et al.,
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1990; Bowen etal., 1989), but it has never been directly tested for its ability to 
specifically detect lymphocytes which home to human lymph nodes. This 
study set out to test whether it had an obvious homing function in humans using 
two - colour flow cytometry (Section 2.2.3A4) to measure the LEU-8+ 
populations on human axillary lymph nodes and peripheral blood.
1.4.2.3 CD 44
In humans, the CD44 (as well as Hermes, pgp-1, HUTCH-1, ECM-III, 
In (Lu)-related p80) cell surface antigen is involved in lymphocyte binding to 
HEV, lymphohemopoiesis (Miyake et d ., 1990), tumour metastasis (Section
1.4.3) and cell activation (Haynes et d., 1989; Coombe and Rider, 1989). 
Unlike the MEL-14 antigen, CD44 is a ubiquitous glycoprotein molecule found 
in different organs and tissues (Dalchau et al., 1980), and existing in different 
isoforms, that derive from the differential splicing of a single CD44 gene 
transcript, diversified molecular weight and numerous functional roles.
The CD44 molecule was originally described by Dalchau etal. (1980) as 
a human molecule defined by monoclonal antibody FI0-44-2. FI0-44-2 
antigen, encoded in the short arm of human chromosome 11 (Goodfellow et d . , 
1982), is expressed during T-cell maturation and widely distributed on T cells, 
granulocytes, brain cells and on cortical thymocytes (Flanagan et d ., 1989). 
Other groups had described a polymorphic major surface glycoprotein of 80 
kDa, expressed on T-cell precursors from mouse 3T3 cells, named phagocytic 
glycoprotein-1 (pgp-1), which was encoded in murine chromosome 2 (Hughes 
and August, 1981; Hughes etd ., 1983; Jacobson et al, 1984). This pgp-1 
antigen was subsequently named Ly 24 and has at least two alleles, such as Ly-
24.1 and Ly-24.2 according to various mouse strains (Lynch and Ceredig, 
1989). Also in 1982, Carter described a 90 kDa surface molecule of human
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fibroblasts, called extracellular matrix receptor type III (ECM-III), that was 
associated with the cytoskeleton, and bound both types I and VI collagen and 
fibronectin (Carter and Wayner, 1988). Haynes etal. (1983) identified an 80 
kDa molecule (p80) on erythrocytes and T cells, regulated by the rare autosomal 
dominant Lutheran inhibitor (In(Lu)) gene (Haynes et al., 1983). This 
antigen is required during intrathymic T-cell maturation and involved in cell 
adhesion and T-cell activation. In 1986, Jalkanen et al. described the Hermes 
series of antibodies (Hermes 1, 2 and 3) mediating lymphocyte - endothelial cell 
binding. Hermes-1 reacts with lymphoma cell lines that bind to either PLN or
PP HEV, and Hermes-3 blocks the binding of lymphocytes to HEV in either 
mouse PP or human appendix, but not to mouse or human PLN HEV. 
Hermes-1 and Hermes-3 have different HEV-binding specificities. Gallatin et 
al. described a p90 molecule called HUTCH-1 involved in lymphocyte- 
endothelial cell binding (Gallatin et al., 1989) and upregulated in T-cell 
activation. At the Third International Workshop on Leukocyte Differentiation 
Antigens, this molecule was named CD44 in humans.
The CD44 molecule is an acidic, sulphated protein that is synthesised 
with the addition of chondroitin sulphate side chains yielding a higher molecular 
weight form of 180-200 kDa, that contains 0-1 inked and N-linked 
oligosaccharide side chains, multiple phosphoserine residues and several 
intrachain disulphide bonds (Jalkanen et al., 1988) (Figure 1. 17). A subset 
of lymphocyte CD44 molecules is modified by covalent linkage of chondroitin 
sulphate (Jalkanen et al., 1988). Chondroitin sulphate is involved in 
endothelial cell recognition of lymphocytes. The chondroitin sulphate form of 
invariant chain can function as an accessory molecule at the cell surface, 
facilitating T cell interaction with APCs through interaction with CD44 
(Naujokas et al., 1993). The binding site on fibronectin is the COOH- 
terminal heparin binding domain (Jalkanen and Jalkanen, 1992). CD44 has 
significant homology to functional domains in the cartilage link protein and the
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cartilage proteoglycan monomer for hyaluronate receptor. Link proteins can 
also bind to native collagen (Chandrasekhar et al., 1983). Thus, CD44 linked 
with cartilage protein in the amino - terminal sequence by differential 
glycosylation or expression of structurally similar CD44 variants (Section
1.4.3) represents a polymorphic family of cell adhesion molecules for diverse 
cell - cell and cell - matrix interactions. Comparison of cloning and 
sequencing with MEL-14 gene shows that CD44 is structurally unrelated to 
MEL-14 (Siegelman et al., 1989). The cytoplasmic tail domain has a variable 
length of three residues (Goldstein et al., 1989) or 72 amino acids 
(Stamenkovic et al., 1989) by spliced exons encoding the carboxyl - terminal 
sequences. Alteration in the length of the cytoplasmic tail may modulate 
intracellular signalling, as the cytoplasmic tail has potential sites for the action of 
both protein kinase A and C (Camp et al., 1991). The larger cytoplasmic tail 
is involved in the interaction of CD44 with cytoskeletal elements (Kalomiris and 
Bourguigon, 1989) which has functional implications in cell adhesion and 
migration. The effective organ specific component of lymphocyte - HEV 
interaction is mediated by synergy of multiple adhesion molecules, such as 
VLA-4, CD44 and other molecules (Holzmann et al., 1989). That is, CD44 
regulates the rapid appearance of Ca^+-, Mg^+-independent, LFA-l/ICAM-1, 
CD2/LFA-3, and VLA-4/VCAM-1-independent adhesion in lymphocyte - 
endothelial cell interaction (Toyama-Sorimachi et al., 1993). Soluble 
circulating CD44 molecules potentially regulate lymphocyte homing and other 
types of CD44 - mediated cellular interactions. Expression of CD44 is 
dependent on the stage of T-cell differentiation, and upregulation of CD44 
expression on T cells is an early event during T-cell activation via the CD3 - 
TCR complex (Willeford et al., 1989). The ligated CD44 molecule initiates 
an activation cascade for a variety of T cell - mediated functions that may use 
protein tyrosine kinase - dependent signal transduction pathways at least in part 
similar to those of the CD3/TCR complex (Galandrini et al., 1993), and can
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direct a transmembrane signal for natural killer (NK) cell activation (Tan et al.,
1993).
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Figure 1.17 Schematic presentation of the CD44 molecule.
-• represents potential N-linked glycosylation (-CHO-); 
- o  represents chondroitin sulphate glycosaminoglycan 
chain in proteoglycan variant (*).
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1.4.3 CD 44 and Metastasis
Activated lymphocytes and metastasising tumour cells share many 
properties, including invasive behaviour, migration involving reversible 
adhesive contacts, accumulation and expansion in draining lymphoid tissue, 
release into the circulation and extravasation (Reviewed by Herrlich et al., 
1993). Metastatic spread involves interaction between tumour cells and 
extracellular matrix (ECM) as well as between tumour cells and endothelial 
cells. Thus, metastasising tumour cells mimic the trafficking of lymphocytes. 
Tumour cells carry various members of the integrin family that are involved in 
the metastatic spread. After lymphocytes contact antigen, they transiently 
express a variant of CD44 (CD44v) which is involved in B and T cell activation 
in vivo (Arch et al., 1992). The CD44 protein is normally present as 
numerous isoforms, considerable size heterogeneity producing functional 
changes, created by mRNA alternative splicing (Jackson et al., 1992). This 
glycoprotein CD44v shares exon V6 (metastasis) sequences with a variant 
causally involved in metastasis formation. The 85 kDa form, presenting as 
smallest splice product involved in lymphocyte homing, is found on the surface 
of many cancer cells irrespective of their metastatic abilities (Pals et al., 1989). 
The mode of action of CD44 V6 variants may resemble that of the 85 kDa 
isoform in that both mediate interaction with the ECM and possibly other cells 
and promote growth probably indirectly. Activated lymphocytes and 
metastasising tumour cells bind a specific ligand in the lymph nodes through 
CD44 V6 variants (Figure 1.18). In rat model systems, antibodies to the 
common variant portion of these variants block the settlement of the tumour 
cells in the draining lymph nodes and block consequendy any further spread 
(Gunthert et al., 1991). On the other hand, Seiter et al. (1993) reported that a 
monoclonal antibody binding within this variant part of CD44 interferes with
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are in a process of activation probably express CD44v. Activated human T 
lymphocytes upon stimulation by mitogen or antigen and aggressive human 
non-Hodgkin's lymphomas (NHL) upregulate expression of a homologue of 
the rat metastasis - associated variant of CD44 (Koopman et al., 1993). A
significant proportion of aggressive NHLs overexpress CD44 variants that 
carry the metastasis - associated exon V6. Moreover, overexpression of the 
metastasis - specific CD44 variants in nonmetastasising tumour cell lines led to 
lymphogenic metastatic spread. Splice variants containing V6 are also 
expressed on several normal human epithelia and on carcinoma lines from lung, 
breast and colon.
1.4.4 Lymphocyte Homing to Regional Tissues
High endothelial cells express organ-specific HEV ligands for 
lymphocyte attachment and that lymphocytes express complementary organ- 
specific homing receptors (Figure 1.19). The specific interaction between 
lymphocytes and flat-walled vessels in a particular organ is similar to that of the 
HEV within the associated lymphoid organs.
Peripheral Lvmnh Node and Pevetis patches
PLN and PP HEV express distinguishable HEV - ligands for 
lymphocyte homing. Some lymphoma lines bind exclusively to PP HEV, 
others to PLN HEV, and still others bind well to HEV in both organs (Butcher 
et al., 1980). Mesenteric lymph node (MLN) blasts bind to HEV in section of 
gut - associated Peyer's patches better than to HEV in PLN.
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Breast
The specificity of lymphocyte homing to endothelial - binding in the 
lactating breast is similar to the small intestine has been supported by studies 
with the monoclonal antibody MECA-367 (Streeter et al., 1988).
Lung
Lung lymph node (LuLN) blasts localised poorly within the intestine, 
instead, these cells entered lung - associated nodes better than did PLN and 
mesenteric lymph nodes (MLN) blasts (McDermott and Bienenstock, 1979). 
While MLN and LuLN blasts are retained equally well within the spleen or 
liver, MLN blasts enter the intestine five times better than LuLN blasts, and 
LuLN blasts enter lung twice as well as MLN blasts. The lymphocyte 
population in the lung is composed of 15% B-cells and 62% T-cells (almost all 
of which are of the CD4 subset) (Yednock and Rosen, 1989).
Naive and Memorv/Effector Lymphocytes
Naive lymphocyte populations (CD45RA+) (not yet stimulated by 
antigen) express homing receptors (L-selectins), which mediate the selectin 
interaction for lymph node homing, and can bind promiscuously to several 
types of HEV. Naive B cells are IgM+, IgD+ and most exist in efferent 
lymph and thoracic duct as the naive type. Memory/effector cell precursors 
(CD45 RO+) express limited sets of homing receptors and increased levels of 
LFA-1 CD2 and VLA-4, all of which promote adhesion to endothelial cells, and 
have migratory or homing specificities restricted to the anatomic site of the 
original antigen stimulation.
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Figure 1.19 Diagram of organ-specific lymphocyte attachment to HEV of 
different lymphoid tissues.
When B and T cells are compared, they show different migratory behaviour 
through various lymphoid and non - lymphoid tissues. Whereas B cells bind 
preferentially (twofold to threefold) to PP HEV and T cells bind better (1.5 
fold) to PLN HEV, both cell types bind equally well to HEV in the bronchus 
tissue. Moreover, within a certain class of lymphocyte, the state of
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differentiation or activation affects the distribution and migration of such 
lymphocytes. The CD4 and CD8 T cell subsets also show slight binding 
differences to PLN HEV (Kraal et al., 1983). Each of these subpopulations 
express both PLN- and PP-specific homing receptors, but one receptor type is 
expressed to a relatively higher degree on the cell surface.
1.4.5 Adhesion
1.4.5.1 Involvement of carbohydrates as recognition determinants in cell
adhesion
Carbohydrates are ideal candidate recognition determinants or 
informational molecules because of their enormous potential for structural 
diversity (Rademacher et al., 1988). Carbohydrates can carry much more 
information per unit weight than either nucleic acid or proteins because of their 
greater potential for structural diversity. All cell - surface carbohydrates serve 
as targets for receptors involving lectins, antibodies, toxins, enzymes, 
hormones, cancer cells, viruses and bacteria or have some other informational 
role. Carbohydrate - directed receptors are also important in lymphocyte 
attachment to HEV. The recognition determinants of the HEV ligands contain 
carbohydrates as essential elements. The lymphocyte attachment activity of 
PLN HEV is abrogated by treatment with a variety of sialidases (Rosen et al., 
1989). Imai et al. (1991) identified an endothelial ligand for PLN homing 
receptor as 50 and 90-kDa sulphated, fucosylated and sialylated glycoprotein 
(Sgp50, Sgp90; sulphated glycoprotein), indicating that sialylation of the 
component is a required component of the recognition determinant. As 
mannose-6-phosphate (M6P) inhibits lymphocyte attachment to PLN HEV, 
apparently by competing with the PLN homing receptor, it was relevant to 
determine whether M6P moieties are essential for the activity of PLN HEV
Table 1.2 Families of adhesion molecules and their counter-receptors involved in 
leukocyte binding to endothelium. LFA; Lymphocyte Function associated Antigen, 
ICAM; Intracellular Adhesion Molecule, VCAM; Vascular Cell Adhesion Molecule, 
NCAM; Neural Cell Adhesion Molecule, PECAM; Platelet Endothelial Cell 
Adhesion Molecule, Mac-1; Macrophage-1, VLA; Very Late Antigen, LPAM; 
Lymphocyte - Peyer's patch Adhesion Molecule, LCAM; Liver Cell Adhesion 
Molecule, MadCAM; Mucosal Addressin Cell Adhesion Molecule
/
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Adhesion Molecule Counter - Receptor Implicated in : Main Tissue Distribution
I?  Suuerfam ily
CD2 LFA-3 T cells
LFA-3 (CD58) CD2
ICAM-1 (CD54) LFA-1, Mac-1 Secondary Widespread
Adhesion
ICAM-2/ICAM-3 LFA-1 Secondary Mostly endothelial cells/
Adhesion All Leukocytes
VCAM-1 YLA-4 Homing to
inflamed tissues
NCAM (CD56) NCAM, Heparan All tissues including
Sulphate nerve cells and NK cells
PEC AM-1 (CD31) ? Platelets, Leukocytes
Endothelial cells
In teeiin  Fam ily
LFA-1 (CDlla/CD18) ICAM-1, ICAM-2 Leukocytes
(aL p2)
Mac-1 (llb/CD18) ICAM-1. C3b NK cells, Monocytes,
(cxMB2) Granulocytes
pl50,95 (CD 11 c/CD 18)) ? Mostly granulocytes,
(cxxp2) Monocytes, NK cells
Lymphocyte Subsets
VLA-1 (CD49a/CD29) Laminin, Collagen Widespread
VLA-2 (CD49b/CD29) Laminin, Collagen Widespread
7LA-3 (CD49c/CD29) Laminin, Collagen, Widespread
Fibronectin
YLA-4 (CD49d/CD29) Fibronectin, VCAM-1, Widespread
(o4pi) cx4p7 Peyer's patch Homing
VLA-5 (CD49e/CD29) Fibronectin Widespread
VLA-6 (CD49f/CD29) Laminin Widespread
LPAM-2 (CD49d/CD-) ? Widespread
GpIIb/1119 (CD41/CD61) Fibrinogen
CD51/CD29 Fibronectin
CD51/CD61 Vitronectin,
MadCAM-1 Fibrinogen, Thrombospondin 
cx4p7
Gut Homing
cx6pl ? Thymus Homing
Selectin Fam ily
E- Selectin sLevisx antigen Leukocyte Rolling
L- Selectin Vascular Addressins Lymphocyte Homing,
Leukocyte Rolling
P- Selectin (CD62) p i50 sLevisx(CD15) Leukocyte Rolling
Cadherin Fam ily
Uvomorulin Homophylic
LCAM Homophylic
E- Cadherin Homophylic
N- Cadherin Homophylic
P- Cadherin Homophylic
Unclassified
CD 44 Hyaluronic acid Many Functions Ubiquitous
Sialylated CD 15 E- Selectin
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and the Ig superfamily includes the antigen - specific receptors of T and B 
lymphocytes (Springer, 1990).
Selectins
The selectins are integral membrane proteins characterised by an amino - 
terminal lectin - binding domain, epidermal growth factor (EGF) - like repeated 
domain and further repeated elements based on complement binding proteins 
known as short consensus repeats (SCRS). The selectins, namely L-, E- and 
P- selectin, are involved in the phase of 'tethering' and 'rolling' of leukocytes to 
endothelium under conditions of flow, and direct their entry into inflamed 
tissues. P- (previously celled PADGEM or GMP 140), E- (previously named 
ELAM-1) and L- selectin (involved in the lymphocyte homing receptor; Section 
1.4.2.2) all function as Ca^+ - dependent lectins recognising sialylated, 
fucosylated and sulphated (not E- selectin) glycoconjugates, particularly the 
sialylated Lewis x antigen (sLex) (Hogg and Landis, 1993). IL-2 induces L- 
selectin down-regulation, whereas IL-6 and particularly TGF-1 promote L- 
selectin up-regulation. Local microenvironments within particular secondary 
lymphoid tissues influence homing receptor expression at the time of CD45 
RA/RO conversion, and thereby contribute to the formation of CD45^ovv/R0^ 1 
memory/effector T cell populations with tissue - selective homing behaviour 
(Picker et al., 1993). A single ligand for P- selectin is a homodimer of 120 
kDa subunits conjugated with O-linked carbohydrate (Moore et al., 1992). 
The effect of leukocyte binding to P- selectin allows a tumbling movement of 
the leukocyte over the endothelial surface before it is completely arrested by a
89
second interaction between the LFA-1 on its surface and ICAM-1 on the 
endothelial surface (Lawrence and Springer, 1991; Fawcett and Harris, 1992). 
E- selectin is an inducible endothelial cell surface molecule that mediates the 
adhesion of neutrophils to activate endothelium (Bevilacqua et al., 1989) and 
the adhesion of a subpopulation of resting CD4+ memory T cells to activated 
endothelium (Shimizu etal., 1991). Both E- and S- selectin bind to specific 
sialylated carbohydrates.
Integrins
The integrins, heterodimeric proteins consisting of a  and P polypeptide 
chains of approximately 1,100 and 750 amino acids that are noncovalently 
associated and mediate the firm addition and endothelial transmigration phases 
of leukocyte entry into inflamed tissue. Both integrin subunits are required 
for ligand binding which is dependent on the presence of magnesium and 
calcium. The a  subunit has divalent cation binding sites and P subunit is 
linked between the ligand and the cytoskeleton. The pi subunit interacts with 
a cytoskeletal protein, and the pi and P3 subunits have sites for tyrosine 
phosphorylation. Integrin binding capabilities vary with cell type, indicating 
that at least some of the transition stages to full activation status can be stable. 
Lymphocytes bind the mucosal vascular addressin MadCAM-1, an Ig 
superfamily adhesion molecule that has a complex multidomain receptor, via the 
a4p7 integrin. The interaction of a4P7 with vascular MadCAM-1 may play a 
critical role in regulating lymphocyte homing to mucosal sites in Peyer's patches 
(Berlin etal., 1993; Briskin etal., 1993). Very late antigens (VLA)-4, so 
called because they appear late in the course of leukocyte activation, bind both 
an extracellular matrix component, fibronectin, and a cellular ligand on 
endothelial cells, vascular cell adhesion molecule (VCAM), which appears late 
after cytokine stimulation of endothelium. LFA-1, consisting of a 180 kDa a
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chain and a 95 kDa (3 chain, predominates over VLA-4 during the interaction of 
leukocytes with their targets. LFA-1 can function in parallel with the MEL-14 
antigen to strength the adhesion of lymphocytes to PLN HEV, and presumably 
with different homing receptors for interaction with other HEV. The adhesive 
contribution of LFA-1 can vary depending upon the strength of the homing 
receptor interaction. Both the LFA-1 and VLA-4 integrins play major roles in 
T-cell adhesion to activated endothelium by binding their respective cell surface 
ligands, ICAM-1 and ICAM-2 (for LFA-1) and VCAM-1 (for VLA-4). Fresh 
T cells and monocytes use LFA-1 with the assistance of VLA-4 to bind 
stimulated endothelium, whereas neutrophils, which lack VLA-4, depend on 
LFA-1 with the assistance of CD3/Mac-1. A counter - receptor for LFA-1, 
ICAM-1 is expressed on a wide variety of cells and its induction in 
inflammation is an important means of regulating LFA-l/ICAM-1 interactions. 
ICAM-1 and ICAM-2 are much more similar to one another, and thus represent 
a subfamily specialised to interact with LFA-1. Ligand or antibody binding to 
integrins stimulates the tyrosine phosphorylation of a cytoplasmic kinase called 
p p l2 5 ^ K  Thus integrins and other classes of adhesion receptors, may 
signal by mechanisms similar to the T-cell antigen receptor, which itself has no 
intrinsic enzyme activity, but interacts with proteins in a larger functional 
complex (Gumbiner and Yamada. 1992).
Immunoglobulin superfamilv
The Ig superfamily consists of molecules that share the basic structure 
of immunoglobulin, composed of 90-100 amino acids arranged in a sandwich 
of two sheets of anti-parallel p-sheets, which is usually stabilised by a 
disulphide bond at its centre (Springer, 1990). The polypeptide backbone is 
arranged as domain structures, and each domain is built from multiple P-pleated
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sheets of amino acid residues. This superfamily has intradomain disulphide 
bridges between cysteine residues, and a transmembrane hydrophobic region 
and a variable - length cytoplasmic domain. ICAM-3, homologous to ICAM- 
1 and ICAM-2, is expressed on lymphocytes, monocytes, neutrophils, 
endothelium and epithelium. ICAM-3 has a key role in the initiation of 
immune proliferative events. ICAM-1 can serve as a pathogenic adhesion 
molecule for the infected erythrocyte stage, which spares the physiological 
interaction with LFA-1. The extent of glycosylation on ICAM-1 may regulate 
adhesion to LFA-1 or Mac-1 in vivo (Diamond et al., 1991). Two binding 
sites of VCAM-1 are involved in the firm adhesion of leukocytes to 
endothelium. CD31 functions as a homotypic adhesion receptor on 
endothelium and activates the adhesion mechanisms of naive CD8+ T cells 
(Tanaka et al., 1992), since CD31 can potently induce integrin-mediated 
adhesion. Expression of CD31 is regulated by phosphorylation of serine and 
tyrosine after T-cell activation. CD59 acts as a second ligand for murine and 
human CD2. CD58 and CD59 function synergistically to activate T-cells via 
CD2.
Cadherins
Cadherins are single - chain integral membrane proteins that are 
homotypic adhesion molecules, and cadherin binding is calcium dependent. 
Cadherins interact with specific populations of cytoskeletal elements. The 
function of cadherins is not only adhesive but serves another role in organising 
the polarity of epithelial cell layers (McNeill etal., 1990).
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1.4,5.3 Cytokines and cell adhesion
When a tissue is infected, it defensively secretes proteins called 
cytokines, such as IL-1 and tumour necrosis factor (TNF). Cytokines 
produced within the tissue are important inducers of leukocyte subset - specific 
adhesion. Cytokines are emerging as excellent candidates for physiological 
adhesion triggers (Rot, 1992). They are released at sites of inflammation, act 
at short distances and induce inflammatory infiltrates of leukocytes in vivo. 
Proteoglycans (PGs) are one of the ECM components that participate in the 
molecular events that regulate cell adhesion, migration and proliferation, 
responsible for immobilisation of pro - adhesive cytokines. Proteoglycans are 
proteins modified by the addition of glycosaminoglycan (GAG) which are long 
linear polysaccharide chains made up of disaccharide subunits. This form 
enhances the formation of multiple cytokine binding sites to provide enormous 
diversity and flexibility to cytokine - cell interactions, thereby yielding a 
mechanism for the control of tissue - specific trafficking (homing) of circulating 
lymphocytes. Cell surface heparan sulphate (HS) PGs are necessary for the 
formation of stable local adhesion sites on fibronectin - coated substrates (Wight 
etal., 1992). ECM proteoglycans bind cytokines/growth factors (Nathan and 
Sporn, 1991), and then proteoglycans mediate the initial uptake and 
presentation of the cytokine to receptors on the same cell (Rapraeger et al. ,
1991). Finally, cytokines bound to proteoglycans on one cell can be 
presented to passing leukocytes that have come into contact with the 
endothelium after the initial tethering step of the adhesion cascade.
IL-8 can trigger granulocyte addition to endothelial ligands via (32 
integrins (Huber et al., 1991) and the macrophage inflammatory protein (MIP- 
1 (3) can trigger adhesion of T-cell subsets to the vascular cell adhesion molecule 
(VCAM-1) via (31 integrins. MIP-lp is localised at the high endothelial 
venules of reactive lymph nodes which are the site of lymphocyte migration into
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lymph nodes. MIP-ip and other cytokines with glycosaminoglycan - binding 
sites bind to and can be presented by endothelial proteoglycans to trigger 
adhesion selectively not only of lymphocyte subsets, but also of other cell types 
(Tanaka et al., 1993). Transmembrane growth factors also promote cell - cell 
adhesion and signalling that leads to proliferation and differentiation of cells. 
The endothelial receptor, vascular addressin, is inducible by severe pro - 
inflammatory cytokines, including TNF-a and IL-1 p. Degradation of L- 
selectin is induced by granulocyte-macrophage-colony-stimulating factor (GM- 
CSF) and TNF-a (Nathan and Spom, 1991). Resting lymphocytes do not 
express ICAM-1, which is rapidly induced after treatment with IL-1, TNF-a, 
and to a lesser extent with IFN-y (Springer, 1990).
1.4.5.4 Cell adhesion and migration
Lymphocytes not only adhere strongly to inflamed endothelium and play 
a critical role in the inflammatory response (Osborn, 1990), but they also 
interact in a precisely regulated fashion with normal endothelium and thereby 
migrate into lymphoid and nonlymphoid tissue (Stoolman, 1989; Shimizu et al., 
1992). Adhesion sites are continually disrupted and reformed as cells change 
shape and move. Chondroitin sulphate (CS) PGs and hyaluronan destabilise 
adhesion sites promote cell motility, while the PGs that contribute to the 
formation of tight cellular adhesion sites inhibit cell migration (Wight et al.,
1992). Cells of different lineages (e.g. T cells vs. neutrophils vs. platelets) 
and subsets within each lineage, such as CD4+ and CD8+ T cells, differ in their 
interactions with endothelial cells, which results in distinct patterns of 
migration. Native and memory T cells have different trafficking patterns. 
Memory T cells preferentially migrate into both normal and inflamed 
nonlymphoid tissue. Naive T cells account for most of the torrent of cells
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entering lymph nodes. Memory CD4+ T cells express higher levels of several 
adhesion molecules than do naive CD4+ T cells. The enhanced expression of 
LFA-1, VLA-4, VLA-5 and VLA-6 on memory cells is associated with their 
increased capacity to bind to the relevant ligands ICAM-1, VCAM-1, 
fibronectin and laminin. Fibrinogen binding to a variety of vascular cell 
receptors mediates a specific pathway of cell to cell adhesion by bridging 
together leukocytes and endothelial cells (Languino et al., 1993). 
Inflammation not only influences the influx of memory cells into nonlymphoid 
tissue, but also dramatically increases lymphocyte (presumably naive T cells) 
entry into lymph nodes. Lymphocyte adhesion and migration to endothelial 
cells clearly involves multiple adhesion molecules - ligand interactions, and 
follow sequences of events (Figure 1.20). Stimulation of PKA and PKC 
induces lymphocyte binding to endothelial cells via different adhesion 
molecules (Turunen et al., 1993). In step 1, inflammatory cytokines induce 
endothelial adhesion molecules and rolling of leukocytes. L- selectin and E- 
selectin mediate adhesion of resting T cells to endothelium, and initiate the rapid 
reaction rate of the carbohydrate - lectin interactions. The cytoplasmic domain 
of L- selectin regulates leukocyte adhesion to endothelium independent of ligand 
recognition, by controlling cytoskeletal interactions and/or receptor avidity 
(Kansas et al., 1993). Step 2 is a triggering of lymphocytes by chemokines
or molecules such as CD31 that activates integrins. Weak binding of VLA-4 
to VCAM-1 on the endothelium provides a feedback loop to augment integrin 
adhesion. A rapid receptor - mediated activation event involving G protein 
signalling can trigger stable lymphocyte attachment to HEV in vivo, and may 
play a critical role in regulating lymphocyte homing (Bargatze and Butcher,
1993). In step 3, conformational changes of integrins play a major role as the 
main adhesive force that results in strong adhesion. The predominant 
pathways are thought to be VLA-4 - VCAM-1, LFA-1 - ICAM-1, and LFA-1 - 
ICAM-2. Lymphocyte sticking can occur within 1-3 sec after initiation of
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Figure 1.20 The sequence of events involved in the binding and 
transendothelial migration of lymphocytes
rolling. Finally, the lymphocyte migrates through the endothelium into the 
surrounding tissue. This requires a reduction in adhesion, followed by 
orderly migration. Degradative enzymes, produced by either the lymphocyte 
or high endothelial cell (HEC), may also be required for lymphocyte penetration 
of the HEV basement membrane. The majority of HEC in contact with 
lymphocytes have their Golgi complexes oriented toward the lymphocyte, 
whereas HEC not in contact have their Golgi's oriented toward the luminal 
surface. The fact that lymphocytes exhibit directed migration from the lumen
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to the parenchyma of the lymphoid organ suggests the possibility that a 
haptotactic or chemotactic gradient directs the migrating cells (Czinn and Lamm, 
1986).
1.4.5.5 Adhesion and cancer metastasis
Cell adhesion molecules play a role in diseases, such as metastasis - the 
spread of primary cancer cells from the main tumour throughout the body to 
induce secondary tumours. Tumour cells exit from the primary tumour by 
penetrating the walls of channels in the vascular and lymphatic circulatory 
systems, and induce their own supply of new blood vessels, called 
angiogenesis. A malignant tumour has a poorly defined border, called the 
invasion front. Any branch of the vascular tree within a tumour mass is a 
potential site for the discharge of cells into the circulation, and the lack of 
lymphatics in tumours may contribute to the build up of hydrostatic pressure 
within the tumour mass (Liotta, 1992). Local growth factors, hormones 
produced by the host and autostimulatory growth factors produced by the 
tumour cells themselves stimulate that proliferation. After the adhesion of the 
tumour cell to the basement membrane, destructive enzymes, such as 
metalloproteinases, are secreted by the tumour cell to cleave or unravel 
basement membrane molecules, such as collagens, in the extracellular matrix 
making up the structural backbone of the basement membrane barrier. 
Subsequently, the tumour cell's pseudopodia (amoeboid false feet) protrude 
into the zone of lysis, followed by migration of the entire tumour cell. TTMP 
(tissue inhibitor of metalloproteinase) (Liotta et al., 1991) produced in normal 
tissues, such as cartilage and bone, as well as tumour cells and nm23 
(nonmetastatic 23) protein (Leone et al., 1991) suppress the invasion and 
metastasis.
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The array of carbohydrates on cancer cells is strikingly different from 
that on normal ones, and cancer cells have unusual carbohydrates on their 
surface, which may account for many of their invasive properties.
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Figure 1.2 1 Diagram of antiadhesive therapy
Tumour metastasis and invasion are mediated not only by tumour cell lectins but 
also by carbohydrates on the surfaces of cells (Sharon and Lis, 1989). The 
carbohydrate recognised by E-selectin is expressed on cells from diverse 
tumours, and at least one type of human cancer cells binds specifically to E- 
selectin expressed on activated endothelium. Some malignant cells recruit the 
adhesion molecules that are part of the body's defences to promote their own
98
metastasis. A number of researchers are attempting to develop antiadhesive 
drugs containing similar carbohydrates could prevent the attachment by binding 
to the lectins, that is, interference of the adhesiveness of abnormal cells, as 
antimetastatic therapy (Sharon and Lis, 1993) (Figure 1.21).
1.5 Monoclonal Antibody Technology
Monoclonal antibody technology, developed by Kohler and Milstein in 
1975, has been applied clinically to the immunoassays, diagnosis and therapy 
of human disease including cancer, immunocytopathology, definition of cell 
surface molecules (Knapp et al., 1989) and modulation of immune responses. 
Recent advances in linkage of toxins and isotopes to monoclonal antibodies and 
in genetic engineering of antibodies (Morrison et al.y 1988) has led to reduced 
immunogenicity, and has improved effector function. Monoclonal antibodies 
are specific for single antigens, can be produced in large quantities from ascites 
fluid or by tissue culture production techniques with high degrees of purity, and 
can be efficiently coupled to isotopes, drugs and toxins. An alternative 
approach for the delivery of cytotoxic agents to cancer cells involves the use of 
monoclonal antibodies as carriers for enzymes to tumour cell surfaces 
(Bagshawe, 1989). The enzymes are chosen for their ability to convert drug 
precursors injected into active antineoplastic drugs. The active cytotoxic 
agents formed can then penetrate nearby tumour cells and cause the death of 
these cells. A number of prodrugs (drugs in an inactive form that can be 
transformed at the tumour into active anticancer drugs by antibody - enzyme 
conjugates) have been developed (Reviewed by Waldmann, 1991a). To be 
effective, antibodies must not cross - react with antigens on normal tissues or at 
least the antigen density should be less than on tumours, and the antigen - 
antibody complex should not dissociate from the cell membrane. For the 
antibody to react with tumour cells, the tumour must be vascular.
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Humanised monoclonal antibodies (Winter and Harris, 1993), 
combination therapy (monoclonal antibody and cytokine or chemotherapeutic 
agent), and bifunctional monoclonal antibodies have been reported to overcome 
the technological barriers to successful antibody - dependent immunotherapy. 
Combination therapy with other biological response modifiers, such as a 
combination of IL-2 and LAK cells incubated with an appropriate monoclonal 
antibody in vitro, might increase the antitumour effect of monoclonal 
antibodies. The anti - Tac monoclonal antibody that blocks the binding of DL- 
2 to IL-2Ra can be useful treatment of patients with human T-cell 
leukaemia/lymphoma virus-I (HTLV-I) (Waldmann, 1991). However, such 
therapeutic strategies remain in early stages and the clinical evidence is on small 
numbers of patients.
1 .6  Aims of Study
1. There is no published report on any antibody generated against the 
lymphocytes localised in human lymph nodes. This study was designed to 
generate antibodies against these cells in order to determine whether they 
contained a marker reactive with lymph nodes.
2. Flow cytometric analysis was used to determine whether the LEU-8+ 
antigen, assumed to be the human lymph node homing receptor, has functional 
homology with the MEL-14 antigen by examining LEU-8 expression in 
matched samples of human nodes and peripheral blood.
3. Several analytical parameters of immunological responses in the nodes and 
peripheral blood were assessed by studying both phenotypic markers and 
activation status of lymphocytes by flow cytometry.
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4. The expression of the human lymphocyte homing receptor CD44 in the 
nodes and the metastasis pattern in both primary tumours and tumour - free/ - 
invaded nodes in breast cancer patients was analysed by flow cytometry.
CHAPTER 2 
MATERIALS AND METHODS
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2.1 Materials
All routine chemicals used in this study except where indicated 
were supplied by Sigma Chemical Company or BDH Chemicals, both of Poole, 
Dorset, England and were of the highest grade available. Plasticware was 
from Sterilin Ltd., Feltham, England.
2.1.1 Cell Culture Reagents
RPMI-1640 Gibco Ltd., Paisley, Scotland
Penicillin/Streptomycin Gibco Ltd., Paisley, Scotland
Foetal Calf Serum (FCS) Imperial Laboratories, Andover, Hants
Cyprofloxacin Bayer, Germany
FCS was inactivated at 56 °C for 30 minutes and all these solutions 
were stored at 4 °C .
2.1.2 Animals
Mice Male and female 8~ 12 weeks old BALB/c
Mice were supplied from the Biochemistry Department colony in 
University of Glasgow.
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2.1.3 Human Tissue
Female patients with breast carcinoma between 
40-90 years old (Courtesy of Professor 
W.D. George, Department of Surgery, 
Western Infirmary, Glasgow)
Patients were not previously treated with chemotherapy and lymph 
nodes were all assessed as tumour free by pathology and flow cytometry.
Peripheral Blood 
and Lymph Nodes
2.1.4 Peripheral Blood and Lymph Node Lymphocyte Preparation
RPMI-1640
Penicillin/Streptomycin (P/S) 
Dimethyl Sulphoxide (DMSO) 
Ficoll - Hypaque
Foetal Calf Serum(FCS)
Gibco Ltd., Paisley, Scotland
Gibco Ltd., Paisley, Scotland
BDH Chemicals Ltd., Poole
Pharmacia Fine Chemicals, Uppsala, 
Sweden
Imperial Laboratories, Andover, Hants
2.1.5 Lymphocyte Population Separation Materials
Petri Dishes Sterilin Ltd., Feltham, England
Sheep Anti-Human IgG Scottish Antibody Production
(H/L chain specific) Unit, Lanarkshire, Scotland
Bovine Serum Albumin (BS A) Sigma Chemical Company
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2.1.6 Buffers
Phosphate Buffered SalinefPBS). pH 7.4
170 mM NaCl
3.4 mM KC1 
10 mM Na2HP04 
1.8 mM HK2P04
Sheath Fluid. pH 7.2 (Flow Cvtometrv Fluid)
1.3 mM NaCl
0.02 mM KC1
20 mM LiCl 
15 mM HK2P04
10mMNa2HPO4
lOmMEDTA
Electrophoresis Running Buffer 
125 mM Tris-HCl, pH 8.3 
660 mM Glycine 
1% (w/v) SDS
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Western Blot Transfer Buffer 
25 mM Tris-HCl, pH 8.6 
0.16M Glycine 
20% (w/v) Methanol 
0.02% SDS
Citrate Buffer. pH 7.6
250 mM Sucrose
40 mM Tri sodium Citrate 2H2O
5% (v/v) DMSO
2.1.7 Enzyme-Linked Immunosorbent Assay (ELISA) Reagents
PBS-Tween 20 BDH Chemicals Ltd., Poole
Orthophenylene Diamine Sigma Chemical Company
(Substrate for HRP)
Anti-Mouse Ig G (y specific) Sigma Chemical Company conjugated HRP
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2.1.8 Cell Fusion Materials
Polyethylene Glycol (M.W. 1500) Boehringer Mannheim, Germany
Hypoxanthine/Thymidine (HT) Sigma Chemical Company
Aminopterin (A) Sigma Chemical Company
Tissue Culture Plates Cambridge, U.S.A.
HAT Medium
HT 1 ml (1/100 to give a final concentration of 0. ImM Hypoxanthine;
0.016mM Thymidine)
A 0.4 ml (1/100 to give a final concentration of 0.4 fiM)
20% RPMI-1640 (20% FCS; 79% RPMI-1640; 1% P/S) 100 ml
2.1.9 Polyacrylamide Gel Electrophoresis Reagents
Acrylamide BDH Chemicals Ltd., Poole
N,N'-methylene bisacrylamide BDH Chemicals Ltd., Poole
N,N,N',N'-tetramethylethylenedi amine BDH Chemicals Ltd., Poole
(TEMED)
Ammonium persulphate BDH Chemicals Ltd., Poole
Sodium dodecyl sulphate BDH Chemicals Ltd., Poole
Amberlite MB-2 (ion exchange resine) Sigma Chemical Company
107
Low molecular weight marker proteins Sigma Chemical Company
Coomassie brilliant blue R stain Sigma Chemical Company
Silver nitrate Johnson Mattey Chemicals
Limited, England
2.1.9.1 Stock solution
Solution A 45% (w/v) Acrylamide
1.2% (w/v) N,N'-methylene bis acrylamide
The solution was deionised with amberlite monobead resin and filtered.
Solution B
Solution C 
Solution D 
Solution E 
Loading Buffer (x5) 
; Stored a t-20 °C
1.5M Tris-HCl, pH 8.8
0.13% (v/v) TEMED
0.65M Tris-HCl, pH 6.8
12% (w/v) SDS
Ammonium persulphate
65mM Tris-HCl, pH 6.8
2% (w/v) SDS
10% (v/v) Glycerol
5% (v/v) 2-Mercaptoethanol
0.001% (w/v) Bromophenol blue
2.1.9.2 Gel preparation
Separating Gel Preparation
12.5% separating gel was prepared from stock solution as follows:
Solution A 16.6ml
Solution B 15ml
Solution D 0.5 ml
Solution E 0.5 ml
TEMED 60|ll
Deionised water 27.4ml
Stacking Gel Preparation
Solution A 2.64ml
Solution C 2.4ml
Solution D 0.2ml
Solution E 0.2ml
TEMED 24pl
Deionised water 8.67ml
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2.1.9.3 Molecular weight markers
lOjil low molecular weight markers proteins mixed with an equal 
volume of loading buffer were runned on the gel.
Protein
Phosphorylase b 
Albumin 
Ovalbumin 
Carbonic anhydrase 
Trypsin inhibitor 
a-lactalbumin
M.W.(subunif)
94.000
67.000
43.000
30.000 
20,100 
14,400
Source
Rabbit muscle 
Bovine serum 
Egg white 
Bovine erythrocyte 
Soybean 
Bovine milk
2.1.9.4 S taining solutions
Coomassie Blue Staining 
Coomassie brilliant blue R stain lg 
Methanol 250mg 
Acetic acid 100ml
Coomassie blue stain was dissolved in methanol acetic acid and then, 
made up to 1 litre with deionised water.
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Silver Staining
Solution A 0.8g Silver nitrate in 4ml deionised water
Solution B 0.36% (w/v) NaOH 21ml
14.8M Ammonia 1.4 ml
Solution C
Solution A was added dropwise with vigorous stirring to solution B and 
then made up to 100ml with deionised water.
Developing Reagent 1% (w/v) Citric acid 2.5ml
38% (v/v) Formaldehyde 250|al
The two solutions were mixed and then made up to 500ml with 
deionised water.
Destain
Methanol 400ml
10% Glacial acetic acid 100ml
Deionised water 500ml
I l l
2.1.10 Monoclonal Antibody Purification 
50% (w/v) (NH4)2S04
Protein A Sepharose CL-4B Pharmacia, Uppsala, Sweden
Dialysis Tubing Medicell International Ltd., London
2.1.11 Fluorochrome Attachment to Immunoglobulin 
0.25M Sodium Carbonate, pH9.0
0.1M Sodium Chloride
Fluorescein isothiocyanate(F!TC) Sigma Chemical Company 
Sephadex G-25M Column Pharmacia, Uppsala, Sweden
2.1.12 The Lowry Protein Assay
2% (w/v) Na/K Tartrate 
1% (w/v) CuS04 5H20
0.1M NaOH / 2% (w/v) Na2C03
2.1.13 Cell Protein Preparation 
0.15M NaCl
Homogenisation Buffer (lOmM PBS, pH7.4;lmM EDTA;0.5M Sucrose) 
Piperazine-N,N'-bis-2-ethane sulfonic acid (PIPES)
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2.1.14 Western Blot
Anti-human IgG Protein A-Peroxidase Sigma Chemical Company
conjugate
Rabbit anti-mouse IgG (whole molecule) Sigma Chemical Company
4-Iodophenol Aldrich Chemical Co.
Ltd., Germany
Luminol: 5-amino-2,3-dihydro- Sigma Chemical Company
1,4-phthalazinedione
2.1.14.1 Photographic materials
X-Omat-S X-Ray Film Kodak Ltd., London
Developer Kodak Ltd., London
Fixer Kodak Ltd., London
2.1.14.2 Chemiluminescence substrate
lOmg 4-Iodophenol was dissolved in 1ml DMSO and added to a 
solution of 40mg Luminol dissolved in 5 ml 0.1 M Tris-HCl, pH8.5. This 
solution was made up to 100ml with 150mM NaCl and then mixed with 32|il 
H2O2 immediately prior to use. This substrate was stored at 4 °C in the
dark.
2.1.14.3 Stain solution for proteins
Stain
0.1% (w/v) Naphthol Blue-Black (Amido black) in 10%.(v/v) acetic acid, 50% 
(v/v) Methanol.
Destain
50% (v/v) Methanol 
10% (v/v) Acetic acid
2.1.15 Solutions for Flow Cytometric DNA Analysis
Stock solution, pH7.6 3.4mM Trisodium citrate 2H2O
0.1% (v/v) Nonidet P40 
1.5 mM Spermine Tetrahydrochloride 
0.5mM Tris
15mg Trypsin (Sigma Chemical 
Company) dissolved in 500ml stock 
solution.
250mg Trypsin inhibitor (Sigma 
Chemical Company) and 50mg 
Ribonuclease A (Sigma Chemical 
Chemical Company) dissolved in 500ml 
stock solution.
Solution A, pH 7.6
Solution B, pH7.6
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Solution C, pH7.6 208mg Propidium Iodide (Sigma
Chemical Company) and 580mg 
Tetrahydrochloride (Sigma Chemical 
Company) dissolved in 500ml stock 
solution.
Solution C was protected against light with tinfoil during preparation. 
All these solutions were stored at -80 °C in 5ml aliquots.
2.1.16 Antibodies for Flow Cytometry
All antibodies were obtained from Dako A/S (Table 4.1) with the 
following exceptions.
Sheep anti-mouse IgG(whole molecule) Amersham International, pic,
FTTC conjugated Bucks
Rabbit F(ab)2 anti-human IgG(y chain) Amersham International, pic,
FTTC conjugated Bucks
Anti-human CD44 FTTC conjugated Sigma Chemical Company
Anti-Leu 8 FITC conjugated Becton Dickinson, Cowley, 
Oxford
2.1.16.1 Miscellaneous
FACScan tubes were supplied by Becton Dickinson, Cowley, Oxford.
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2.1.17 Cell Lines
2.1.17.1 Human B cell lines
Raji was established in 1963 from Burkitt's lymphoma in an 11 old 
Negro male. Growth is in the form of single cells without attachment and as 
macroscopically visible clumps containing many hundreds of cells. This cell 
line produces interferon when stimulated by Newcastle disease virus (Epstein et 
al.y 1986). Raji has no surface immunoglobulin but MHC Class I and MHC 
Class II.
Daudi was established from a 16 year-old male Negro with Burkitt 
lymphoma. The cells have surface IgM very strongly (Klein E. et al., 1968) 
and MHC Class II but no MHC Class I.
Ramos was derived from an American Burkitt's lymphoma which does 
not possess the EBV(Epstein-Barr Virus) genome. Ramos has surface IgM, 
MHC Class I and MHC Class n.
2.1.17.2 Human T cell line
Jurkat E6.1 was derived from Jurkat FHCRC. It is an interleukin-2 
producing cell line, human leukaemic T cell lymphoblast, derived by incubating 
the cells at 41 °C for 48 hours followed by a limiting Jurkat E6.1 dilution 
cloning over macrophages.
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2.2 Methods
2.2.1 Monoclonal Antibody Production
Monoclonal antibodies (Mabs) reactive with lymph node lymphocytes 
were produced by methods described previously (Campbell, 1991). Figure
2.1 outlines the steps in the production of monoclonal antibodies made in this 
study. Balb/c mice were immunised with a highly enriched population of 
nodal cells, and once a good humoral response appeared in the immunised 
animal, screening of serum by FACScan was used to indicate when fusion was 
appropriate. Animals were boosted intravenously with 10^ cells 4 days before 
fusion. Spleen cells from the immunised mice were then mixed with the 
myeloma SP2/0 cells, and fused in 50% polyethylene glycol (M.W. 1500). 
Cells from positive wells were grown in complete medium (89% RPMI-1640; 
10% FCS; 1% P/S) and then single-cell cloned. The resultant monoclonal 
antibodies were screened on FACScan or ELISA and tested as for Leu-8 
(Chapter 4) in some cases with a direct label. Three clones were produced in 
this study, all using separate immunisation schedules. One clone was from a 
mouse immunised with whole lymph node lymphocytes, and two clones from 
mice with immunised with panned nodal T cells, were selected either by 
FACScan or by ELISA.
2.2.1.1 Antigen preparation
In general, fresh intact cells were used since these are excellent antigens, 
particularly for generating monoclonal antibodies to membrane proteins. 
Injection was of 10^ to 10^ cells. In this study the first antigen tested was
unfractionated lymph node lymphocytes. Lymph node cells were collected by
the method described in Section 2.2.2.3. When this response was to be 
dominated by B cells, two further fusions were under taken with enriched
Figure 2.1 The general procedure of monoclonal antibody production
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populations of lymph node T cells. Preparation of T lymphocytes (panning) 
was carried out under sterile conditions at 4 °C. Firstly, two sterile 10cm 
petri dishes were coated with 10ml sterile filtered 130mM NaCl and 0.05M 
Tris-HCl, pH 9.0 containing 0.5ml anti-human IgG (Sheep, H/L chain 
specific). The petri dishes were incubated for 1 hour at 37 °C and then 
overnight at 4 °C. The petri dishes were then washed with 5% BS A and then 
with PBS five times. 5ml lymphocyte suspension adjusted to a cell density of 
10? cells/ml was added to the plate and incubated for 1 hour at 4 °C, gently 
rotating the plate after 30 minutes to allow cells to coat more evenly. The 
plate was tilted and unbound cells were repanned on another plate to remove 
any residual bound cells. Finally, after the repeated panning step the 
supernatant containing the unbound cells was collected and centrifuged at 150g 
to obtain enriched T cells.
2.2.1.2 Immunisation
Primary immunisation was with 10^ cells in saline, intraperitoneally 
four weeks before fusion. This was repeated after 2 weeks to stimulate 
isotype switching and the production of high-affinity antigen induced memory 
cells. After serum test (Section 2.2.1.3), final intravenous boost was with 
105 cells 4 days before the fusion to active the memory B cells in the spleen.
2.2.1.3 Serum collection and FACScan analysis
The sera from tail bleeds was obtained 10 days after secondary 
immunisation and used to check the presence of required antibodies. The 
serum as first antibody was diluted in 1 in 100 with PBS and analysed by 
FACScan. The procedures were followed as described in Section 2.2.3.3.I.
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When the serum titre was positive with an IgG specific probe with respect to 
control serum the mice are rested for a short period of time. The second 
antibody used in this work was anti-mouse IgG (Sheep, y specific) conjugated 
to FITC (Amersham).
2.2.1.4 Cell fusion
Once a good immune response had developed in mice, preparations for 
fusion were made. All operations were performed in the sterile hood. The 
myeloma (SP 2/0) cells used in this study were at least 35% in S-phase of cell 
cycle on the morning of the fusion. 2 x 10^ myeloma cells were harvested in 
sterile universal containers and washed twice with centrifugation at 150g for 5 
minutes and then resuspended in RPMI-1640. The spleen tissue was isolated 
from the immunised mice and put into a 6 cm petri dish containing 5ml RPMI- 
1640. The spleen cells were teased out from the capsule using 21G needles to 
break clumps. The spleen cell suspension was drawn into a 10ml syringe 
through a 21G needle, pipetted out again and this operation was then repeated 
twice with a 25G needle. The spleen cells were washed twice in RPMI-1640. 
The final cell density of spleen cells for fusion was adjusted to 10^ cells. 
Separate aliquots of spleen and myeloma cells were removed for controls. 
The remainder were then mixed together and centrifuged at 150g for 5 minutes. 
The cell pellet was tapped to loosen it and 2ml of PEG (M.W. 1500) solution 
was added evenly over a period of 30 seconds shaking the cells by gendy 
flicking of the tube. The PEG and cell suspensions were dispersed over the 
next 30 seconds with pipetting up and down and then allowed to stand for 30 
seconds. 5ml of RPMI-1640 was then added dropwise evenly to this cell 
suspension over a period of 90 seconds shaking very gently to dilute out the 
PEG slowly and then another 5ml of RPMI-1640 was added immediately. 
The cell suspension stood for 5 minutes and was then centrifuged at 150g for 5
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minutes. The fused cells were resuspended in HAT medium (Section 2.1.8) 
and then 200 |il of this cell suspension was aliquotted into each well of a 96
well plate with the exception of control wells on each plate. The plate were 
incubated in a 5% CC>2 humid incubator at 37 °C.
2.2.1.5 Cell culture and selection of clones
Between 4 and 5 days after fusion, 0.1ml of old medium was gently 
removed and replaced with fresh medium. If the myeloma cells were not dead
they were fed with fresh medium containing HAT. The clones appeared 
clearly 7 days after fusion. When clones were <10^ cells in size, 0.1ml of 
supernatant was removed for assay and replaced with fresh medium without 
HAT. In this point the spleen cells in control wells were important for assay 
to give an indication of background antibody secretion from unfused spleen 
cells. The screening assay was carried out according to Section 2.2.1.6. 
The positive wells of plates were selected and immediately cloned on 96 well 
mouse spleen feeder plates. The cloning by limiting dilution was performed 
according to the method of Goding (1980). A very small number (10^ cells) 
were required for cloning. The relevant positive clones from the fusion plates 
were aspirated by holding the pipette tip vertically over them and removing them 
into 10ml of complete medium. Next, 1 in 2 doubling dilutions were carried 
out as follows:
(a) 2ml from the cell suspension solution above were added to 18ml of 
fresh medium and then plated out at 100 |i.l/well into rows B and C. This was 
approximately 1 cell/well.
(b) This was repeated as in (a) above to give 0.1 cell/well.
(c) This was repeated as in (a) above to give 0.01 cell/well.
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The clones were visualised after 1 week and assayed again. The clones 
secreting desired antibody were selected and recloned using the same strategy. 
Finally, clones positive at the highest dilution was collected and expanded in 
tissue culture flasks containing 10% complete medium. This colony was
grown fully in tissue culture flasks. Some cells were resuspended in freezing
medium (90% FCS; 10% DMSO), and frozen in liquid nitrogen and other cells 
were propagated by injection into mice for ascites fluid production.
2.2.1.6 Screening
The selection of positive clones from cell fusion (Section 2.2.1.5) was 
performed using both ELISA and FACScan analysis. FACScan can detect all 
surface reactive Mabs but is time consuming with >1000 primary clones. 
ELISA readily adapts to mass screening but the cell membranes are inevitably 
breached such that intracellular antigens may dominate the fusion selection.
2.2.1.6.1 ELISA assay
Nodal T cells were stored bound to ELISA plates containing 0.02% 
(w/v) sodium azide (to avoid bacterial contamination) and blocking buffer both 
of which were washed off immediately before use. Freshly prepared ELISA 
plates were coated with lOOfil/well of a T cell suspension of 10^ cells/ml in 
RPMI-1640, and fixed with 0.25% glutaraldehyde for 1 hour at room 
temperature. The plates were washed with PBS and then incubated with 
IOOjj.1 of blocking reagent (5% BSA/PBS) for a minimum of 1 hour at room 
temperature, followed by washing in PBS. 200|il of serum or cell culture
supernatant was added to the second column of the ELISA plate using a 
multipipette with sterile tips and then diluted serially using 5% BSA/PBS as
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diluent. The first column was left with only PBS added as a negative control 
without first antibody and the assay plates were covered with clingfilm and 
incubated for 1 hour at 37 °C before washing twice with PBS containing 0.05% 
Tween 20. lOOji.1 of 1 in 1000 dilution of second antibody (Section 2.1.7) in 
PBS/0.05% BSA/0.01 % Tween 20 was added to all wells, incubated for 1 hour 
at 37 °C, and plates were then washed in PBS/0.05% Tween 20. lOOfil of
substrate solution (0.04 mg/ml orthophenylenediamine in 0.05M Na citrate; 
0.15M Na phosphate; 0.01% H2O2 pH 6.0) was added to each well and
incubated for 15 minutes in the dark at room temperature. The reaction was 
stopped by the addition of 50pl 4N H2SO4 and wells were scanned at 492nm in
a multiscan spectrophotometer.
2.2.1.6.2 FACScan analysis
FACScan screening was only performed on wells where there was a 
clearly visible clone. The stored frozen lymph node lymphocytes in freezing 
medium (90% FCS; 10% DMSO) at -140 °C were washed in PBS twice at 
150g for 5 minutes, and 25pl of culture supernatant from wells of culture plates 
was used as first antibody. The second antibody was FITC labelled anti­
mouse IgG (y chain specific) and the method was carried out according to 
section 2.2.3.3.I.
2.2.1.7 Monoclonal antibody purification
Ammonium sulphate precipitation is one of the most commonly used 
methods for subfractionating proteins from solution. In general, antibodies 
can be separated by affinity chromatography on insolubilised protein A 
according to their heavy chain constant region. This affinity procedure can be
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used to isolate the majority of IgG directly from ascites fluid or culture 
supernatant. The purification technique was followed in the method of
Johnstone and Thorpe, 1987. The 10ml of 100% saturated (>770g/l) 
ammonium sulphate solution at pH 7.0 was added very gradually to 10ml tissue 
culture supernatant or ascites fluid (Section 2.2.1.9) with vigorous stirring 
slowly for 1 hour at 4 °C. The solution was centrifuged at 500g for 20 
minutes at 4 and then the pellet was dialysed overnight in small dialysis
tubing against three changes of PBS at 4 °C. On the next day a small amount 
of filtered sample solution was layered onto the protein A coupled to Sepharose 
CL-4B column (Section 2.1.10) and washed with 5ml 0.1M sodium phosphate 
buffer, pH 8.0. 0.5ml fractions were collected and their absorbance was
monitored at 280nm. The column was eluted with 5ml 0.1M sodium citrate 
buffer, pH 2.5 and 0.5ml fractions were collected directly into tubes containing 
60jul 2.0M Tris-HCl, pH 8.5, to neutralise the solution. The absorbance was 
measured at 280nm and the antibody was stored for immunoassay.
2.2.1.8 Fluorochrome attachment to immunoglobulin
This method was performed with technique of Johnstone and Thorpe, 
1987. The immunoglobulin prepared in section 2.2.1.7 was dialysed at 4 °C 
overnight in 0.25M carbonate buffer to give a protein concentration of 10-20 
mg/ml. 0.05 mg of FITC per mg of protein was added and mixed at 4 °C 
overnight with shaking. The mixture was applied to a Sephadex column 
(Section 2.1.11) and the fractions were eluted with PBS. The
fluorescence/protein ratio was calculated by measuring the absorbance of the 
conjugate at 280nm and 495nm. Three fractions were used for most 
purposes.
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2.2.1.8.1 FACScan analysis
Monoclonal antibodies conjugated to FITC (Section 2.2.1.8) were 
produced as two types: as IgG monoclonal antibody conjugated FITC from 
culture supernatant and ascites fluid and identified using FACScan. IOjj.1 of 
each monoclonal antibody produced was added to antigen and then stained with 
B cell marker CD19 conjugated PE (10pl) or T cell marker CD3 conjugated PE 
(lOfxl). The method in detail was followed in according to section 2.2.3.3.I.
2.2.1.9 Ascites fluid
Expansion of hybridoma cells in vivo was carried out in ascites fluid in 
mice. The mice were primed by the injection of 0.5ml Pristane(2,6,10,14- 
tetramethyl pentadecane) which depresses the normal immune system of the 
mouse so that internally injected cells are able to grow without rejection (Freund 
and Blair, 1982), intraperitoneally using a 21G needle. After 10 days of 
priming, 0.5ml of washed hybridoma cells (10^ cells) in active logarithmic 
growth were injected into the peritoneal cavity of mice using a 21G needle. 7- 
14 days post injection the mice showed abdominal growth and were killed and 
the ascites fluid containing hybridoma and antibody was extracted into a 
heparinised tube by inserting and draining with a 21G needle. The ascites 
fluid was gently layered over 10ml of Ficoll-Hypaque solution and centrifuged
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for 20 minutes at 500g. The supernatant containing monoclonal antibodies 
was collected gently and stored at 4 °C for immunoassay. The hybridoma cell 
layer at the interface was obtained by carefully pipetting, washed in RPMI-1640 
twice at 150g for 5 minutes and then resuspended in 24 well cell culture plates 
containing complete medium.
2.2.2 Preparation and Storage of Lymphocytes
2.2.2.1 Patients
Axillary lymph nodes not invaded with tumour and peripheral blood 
were obtained from breast cancer patients whose age ranged from 40 to 90 from 
the Department of Surgery, Western Infirmary in Glasgow, U.K. Patients 
were not previously treated with chemotherapy and samples of these nodes 
were sent to the Department of Pathology for routine histological examination. 
Histopathological reports confirmed that the nodes were not invaded.
2.2.2.2 Preparation of lymphocytes from human peripheral blood
Peripheral blood was obtained from the same patients on the day of 
surgery. 10ml of blood was stored in potassium-EDTA anti-coagulant until 
ready for processing, usually within 1 hour of removal from the patients. 
Blood was gently layered over on equal volume of Ficoll-Hypaque and 
centrifuged for 20 minutes at 500g. The lymphocyte layer was obtained by 
carefully pipetting from the interface and added to a clean tube. The plasma, 
Ficoll solution and red blood cells were discarded. The cells were washed in 
RPMI-1640 medium twice at with centrifugation 150g for 5 minutes. The 
pellet was resuspended in freezing medium consisting of 90% heat-inactivated 
foetal calf serum and 10% DMSO to achieve a final concentration of 1 x 10^
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cells/ml. This cell suspension was transferred in 1 ml aliquots to freezing 
vials. They were placed in a - 70 ^C freezer overnight and then finally stored 
in a liquid nitrogen freezer for later analysis. On removal from liquid 
nitrogen, cells were thawed quickly in a 37 °C water bath to avoid damage by 
ice crystal formation within the cells and immediately transferred to a universal 
container containing filtered PBS pH 7.4. These cells were washed twice 
with centrifugation at 150g for 5 minutes and resuspended at the required cell 
concentration of 2 x 10^ cells/ml in filtered PBS for FACScan analysis.
2.2.2.3 Preparation of lymphocytes from human lymph nodes
Lymph nodes were also obtained from patients on the day of surgery 
and processed immediately in order to avoid alteration in membrane receptor 
expression. Half of each node transferred into a 60 mm sterile petri dish 
containing RPMI-1640 tissue culture media were teased out using a sterile 
needle and scalpel. The lymphocytes were then harvested, washed by 
centrifugation at 150g for 5 minutes, counted with a Haemocytometer and 
adjusted to 1 x 10^ cells/ml in RPMI-1640 medium. They were then 
resuspended in a freezing mixture and finally stored in liquid nitrogen until 
analysis.
2.2.3 Flow Cytometry
PBLs, LNLs, and other cells used in this study were analysed by flow 
cytometry. Flow cytometry was developed as a technique for quantifying the 
visual picture obtained by microscopic examination of cells stained with specific 
antibodies. It operates by projecting a single cell stream through a focused 
laser beam one at a time. The light scattered from the cells is detected
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by a photomultiplier, recorded and displayed as a two or three-dimensional 
graph on a computer monitor. The main applications of flow cytometry are 
for analysis of the expression of specific cell surface molecules and quantitation 
of cellular DNA using determination of cell cycle phases. The flow cytometer 
used was a Becton-Dickinson designed FACScan (Fluorescence Activated Cell 
Scanner).
FACScan consists of a bench-top cytometer which is a laser driven and 
the computer system and is capable of detecting and analysing cells using 5 
optical detectors. The 5 parameters include 2 physical parameters, consisting 
of forward scatter (FSC) and side scatter (SSC), and 3 different fluorescence 
(red, red/orange and green) components. The FSC parameter detects the 
amount of incident light scattered in the forward direction and measures the cell 
volume. The amount of incident light scattered at 90 degrees is detected by 
SSC parameter which gives the information of the granularity of the cell. The 
specific size and granularity of cells are identified by these parameters, and it is 
possible to distinguish a particular cell population from other cell types present.
2.2.3.1 Mechanical system 
(al Optical system
The laser used in FACScan optical system is ionic, an air cooled 15 mV 
Argon laser set at 488nm. The output beam is transformed into an elliptical 
shape through the refracting beam expander and focus on a stream of cells in the 
flow chamber. The physical dimension of flow chamber limits the numerical 
aperture of the collection lens. The forward collection lens gathers scattered 
light from about 1 to 2 degrees off the laser-beam axis. This angle minimises
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Figure 2.2 Diagram illustrating the generalised optical system of the flow 
cytometer
the effect of refractive index changes and maximises the dependence on particle 
size. The different wavelength are separated by the use of dichromic mirrors 
and adsorption filters. The long wavelength incident at the dichromic mirror 
(dichromic 1) passes on towards the green fluorescence detector and through a
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530nm filter with a 30nm half-peak bandpass, optimised for FITC detection 
(FL 1). The transmitted path scatter is further split from the green 
fluorescence by a Brewster-angle beam splitter which takes advantage of the 
polarised nature of 90 degrees scatter and the mostly unpolarised state of 
fluorescence. The side scatter channel does not require a filter. A 45 degree 
dichromic mirror (dichromic 2) splits off the orange/red fluorescence which is 
optimised for the detection of PE (FL 2) through a 575nm filter with a 42nm 
bandwidth from the red fluorescence. The red fluorescence channel (FL 3) 
has a emission filter which transmits long wavelength light above 650nm 
(Figure 2.2).
(b) Fluidics system
The function of the fluidics system to deliver a laminar, single file flow 
of cells one by one to a specific point in space by the illuminating beam. 
Flow chambers can transport particles to the detection point with an accuracy of 
better than ±1 micron. The sheath fluid line of two fluid lines feeding the 
flow chamber flows isotonic sheath fluid continuously and is controlled by 
regulated air pressure. The sample is driven into the capillary tube, the 
sample line, by a differential pressure. The sample flow rate is controlled by 
a pressure regulation acting on the sample chamber. The high flow rate 
(60|il/min) is suitable for immune monitoring, whereas the low flow rate 
(12fil/min) allows higher resolution in applications such as DNA cell cycle 
analysis.
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2.2.3.2 Fluorochrome dyes
Fluorescence occurs when a molecule excited by light returns to the 
ground state by emitting light of a longer wavelength. The different 
wavelengths between exciting and emitted light can be separated from one 
another using optical filters. The ability to detect fluorescence simultaneously 
from two or three compounds at different wavelengths enables several 
parameters to be measured. Fluorescein-5-isothiocyanate (FITC; 
C12H11NO5S) dye is used to covalently label antibodies giving bright
distinctive fluorescence (FL 1) absorbing at 488nm and emitting a green 
fluorescence signal at 525nm. R-phycoerythrin (PE) is from the 
phycobiliprotein family of highly fluorescent macromolecules (M.W. 240,000).
PEFITC
Fluorescence
Intensity
Spectral
Overlap
500 700550 600 650
Wavelength (run)
Figure 2.3 Diagram of filter transmission for the separation of fluorescence
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PE is required as the label of second chromic and can be excited at 488nm but 
emits at a wavelength of 575nm with a strong orange/red coloured signal. It 
can be easily distinguished from the green fluorescence of fluorescein and 
detected by FL2 channel. For a third dye, propidium iodide (PI) is used to 
perform live and dead cell discriminations by intercalation to double-stranded 
nucleic acid. This dye absorbs at 488nm and emits light at greater than 
650nm detected in the red part of spectrum channel (FL3). The shorter 
wavelengths between 500nm and 650nm pass on towards the FITC 
fluorescence detector and through a 530nm filter. Wavelengths greater than 
650nm are reflected toward the PE fluorescence detector and through a filter 
centred at 578nm. The PI emission covers the range from 550nm to over 
700nm and through a 640nm filter. Emission filters in each of the detector 
channels are selected to minimise spectral overlap (Figure 2.3).
2.2.3.3 Preparation of samples
2.2.3.3.1 General
The cells were washed twice in PBS and resuspended at a final cell 
density of approximately 10^ cells/ml. 50 pi of this cell suspension was 
incubated in the flow cytometry tubes (Falcon 2052) with the appropriate 
monoclonal antibodies (Table 4.1) to specific phenotypic and activation markers 
on the lymphocyte membrane for 20 minutes on ice. All samples were 
maintained in the dark to prevent bleaching of the fluorochrome. In the case 
of double staining, after the initial 20 minutes incubation the cells were washed 
in 1 ml of PBS and centrifuged at 150g for 5 minutes, the supernatant was 
gendy removed, and the cells were incubated in the next antibody for 20 
minutes on ice. After the final incubation step the cells were washed and 
resuspended in 0.3 ml of PBS. Propidium iodide (lOpg/ml) was then added
132
to each tube to discriminate live cells from dead cell populations from the 
analysis. Data on 5000 live cells were then acquired on FACScan.
2.2.3.3.2 Trypsin-detergent method
Preparation of nuclei for flow cytometric DNA analysis was performed 
according to the method of Vindelov et al. (1983) (Section 2.1.15). Nuclei 
were prepared from SP2/0 myeloma cells prior to cell fusion. Firstly, 900fil 
of solution A was added to 200fil of the cell suspension in citrate buffer and the 
contents were mixed by inverting the tube gently. After incubation for 10 
minutes at room temperature, during which the tubes were inverted five times, 
750|il of solution B was added. This was followed by a further 10 minutes 
incubation at room temperature and again the solutions were mixed by inversion 
of the tube. Finally, the cells were stained with 750pl of ice-cooled solution 
C and the tubes were incubated at 4 °C in the dark until analysed between 15 
minutes and 60 minutes later.
2.2.3.3.3 Ethanol fixation method
This work was performed by the cell suspension fixation method of 
Zarbo et al. (1989). The washed cells were resuspended in PBS and then 
distributed into 100pl each to sample tubes. To this cell suspension, lOOjil of 
cold 70% ethanol was added dropwise slowly with vortexing After 
incubation for 30 minutes on ice, the cells were washed in 1 ml PBS for 5 
minutes with centrifugation at 150g and stained with monoclonal antibodies. 
The tubes were again incubated for 30 minutes on ice and centrifuged for 5 
minutes at 150g. Finally, the cells were resuspended in 200p.l PBS and 10|il 
of PI was added to each these while creating access for nuclear DNA dye
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penetration. This method is particularly useful in studies to screen the 
intracellular and cell surface molecules simultaneously with cell cycle analysis.
2.2.3.4 FACScan analysis
2.2.3.4.1 DNA cell cycle analysis
The quantitative analysis of cell cycle distribution was done by 
FACScan flow cytometer using 10,000 nuclei per sample.
Frequency
Relative DNA Content
Fluorescence
Intensity
Figure 2.4 Diagram illustrating flow cytometric analysis of the cell cycle 
together with a DNA histogram
Mitosis Phase
The Cell 
Cycle
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Analysis of such data gives information on both the nuclear content (DNA 
ploidy), which is frequently abnormal in breast tissue, and the S phase fraction 
(SPF), which is the measure of the proliferation rate of a growing cell 
population. Cells in G2/M phase of the cell cycle have double the DNA 
content, while cells in S-Phase will have a DNA content lying between Go/Gl 
and G2/M phase (Figure 2.4). After the nuclei were stained (Vindelov et 
a/., 1983), the data was collected and analysed using available DNA cell cycle 
analysis software. The DNA content measured produces a histogram of the 
number of cells, and this will reflect the cell cycle.
2.2.3.4.2 Discrimination of live and dead cells
Data from cell samples acquired on FACScan were collected by 
removing dead cells by using a live selection gate.
Unstained. Cells 
(Live Celb)
Stained Cells ’vith PI 
(Dead Cells)
Cell
number
FL3 Fluorescence (log)
Figure 2.5 Diagram of collection gate to exclude dead cells stained with 
propidium iodide (PI) from live cell population
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This method makes it possible to collect data from live cells with intact 
membranes and exclude data from dead cells with breached membranes using 
propidium iodide (PI), a DNA stain. PI intercalates with DNA and RNA but 
cannot to do so in the case of cells with intact membranes. Thus dead cells, 
nucleated and non-viable cellular debris, can be preferentially selected and 
excluded on a FL3 channel (Figure 2.5).
2.2.3.4.3 Discrimination of individual cell populations
The specific size and granularity of cells can be identified by using a 
Forward and Side scatter plot and these properties can be used to differentiate 
between lymphocytes, monocytes and neutrophils. It is possible to gate any 
unwanted cells positioning in the lower left hand portion of the Scatter plot 
staining with fluorescently labelled antibodies, and such cells therefore can be 
identified as distinct cell populations on FL1 versus FL2 plot Also drawing a 
gate around the lymphocyte population, it is possible to collect data confined 
only on lymphocytes. Becton-Dickinson software package called "paint-a- 
gate" gives a information about the identification of cell populations in one 
parameter and then identify the same cells in another parameter. In this study, 
all analyses of lymphocytes were performed with both the PI gate and the 
lymphocyte scatter gate. The proportion of cells positive for the phenotypic 
or activation markers were analysed using four quadrant analysis of FACScan 
software. The positive cells were identified on each quadrant according to the 
fluorescence channel and relative percentage of these cells measured on the 
computer.
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2.2.3.4.4 Dual-parameter colour analysis
Dual immunofluorescence techniques have been developed to analyse 
the degree of expression of multiple markers on the surface of cells, enabling 
the fluorescence intensity of multiple monoclonal antibodies (Table 4.1) to be 
measured simultaneously on each cell. Basically, the two fluorescence dyes 
used were fluorescein isothiocyanate (FITC) and phycoerythrin (PE) to perform 
two-colour analysis. The samples were incubated with a primary antibody 
(lOjul), washed, incubated again with second antibody (lOjul) and analysed. 
The positive cells for a given activation marker (FITC labelled) were measured 
on the FL1 channel and another cell population for a PE labelled antibody were 
measured on the FL2 channel. Finally, the distinct double-stained cell 
population was displayed on quadrant 2.
2.2.4 Preparation of Cell Membrane Proteins
This procedure was prepared by the method of Earp et al, 1984. 
Human B cell lines were centrifuged at 150g for 5 minutes and then washed 
twice with 10ml of 0.15M NaCl. The cells were gently resuspended in 2.5ml 
homogenisation buffer (lOmM PBS, pH 7.4; ImM EDTA) and broken by 
sonication on ice. 2.5ml of homogenisation buffer (lOmM PBS, pH 7.4; 
ImM EDTA; 0.5M sucrose) was added to the broken cell solution and 
centrifuged at 150g for 5 minutes to remove nuclei and unbroken cells. The 
supernatant was transferred and centrifuged for 60 minutes at 105,000g in a Ti
70.1 Beckman rotor. Finally, the pellet was resuspended in 20 mM PIPES, 
pH 7.0.
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2.2.5 Estimation of Purification of Cell Proteins
To ensure the method used for preparation of cell membrane proteins, 
the homogenised cells prepared as described in section 2.2.4 were assayed 
according to the Lowry protein assay (Lowry et al. ,1951). Firstly, 400|il of 
the Lowry concentrate (Section 2.1.12) was added to a 400p.1 of sample and 
incubated at room temperature for 20 minutes. After addition of 0.2N Folin 
reagent, this solution was mixed with vortexing immediately and then incubated 
for an additional 30 minutes at room temperature. The samples were 
monitored within 10 minutes of each other on an LBK spectrophotometer at 
500nm absorbance using glass cuvettes. Finally, the protein concentration 
was estimated on the standard curve.
2.2.6 Polyacrylamide Gel Electrophoresis
SDS-polyacrylamide gel electrophoresis was performed according to the 
method of Laemmli (1970). Samples in loading buffer were heated in a 
boiling water bath for 2 minutes and loaded into individual wells in the stacking 
gel. Electrophoresis was performed at a constant current of 45mA for 4 hours 
or 10mA for 18 hours at room temperature until the dye front reached the 
bottom of the gel.
2.2.6.1 Coomassie blue staining
After electrophoresis gel was stained in coomassie blue stain solution 
(Section 2.1.9.4) for 1 hour and then destained until protein bands were 
revealed. The gel was dried onto Whatman 3mm filter paper in a vacuum 
drier at 80
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2.2.6.2 Silver staining
This is a method for highly sensitive staining of a gel developed by 
Wray et al. (1981). The SDS-PAGE gel was fixed in 40% ethanol, 5% 
glacial acetic acid and 55% double deionised water overnight to remove SDS. 
It was then stained in staining solution (Section 2.1.9.4) for 20 minutes with 
gentle shaking and then washed with deionised water with three changes. 
The gel was developed using developing reagent and protein bands were 
appeared within 20 minutes. The reaction was terminated by rinsing the gel in 
50% methanol.
2.2.7 Western Blot
This technique was performed by the method of Batteiger et al. (1982) 
with modifications. After electrophoresis the gel was removed from the gel 
apparatus and placed on Whatman 3mm filter paper keeping it wet with transfer 
buffer (Section 2.1.6) at all stages, avoiding air bubbles. The nitrocellulose 
paper was covered over with a second piece of filter paper and then encased 
between the gause squares within the plastic cassette soaked in the same buffer. 
This assembly was fitted into the transfer tank, in such a way that the 
nitrocellulose paper was nearest to the positive electrode. Electro-transfer was 
achieved at 350mAmps for 4 hours at room temperature and then the 
nitrocellulose paper was blocked in the blocking buffer (5% BSA in PBS, pH 
7.4) for 1 hour at room temperature. Washing was carried out with 3 x 
100ml of buffer PBS, pH 7.4 for over 30 minutes, and nitrocellulose strip was 
incubated with culture supernatant of monoclonal antibody for 1 hour on shaker 
at room temperature. After further washing, the nitrocellulose paper was 
incubated with the second antibody (Section 2.1.14), rabbit anti-mouse Ig G 
(whole molecule) which was diluted in 1/500 with 5% BSA/PBS, pH 7.4 for 1
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hour at room temperature and then washed in the PBS, pH 7.4. Anti-human 
Ig G protein A conjugated peroxidase diluted in 1/500 with 5% BSA/0.01% 
Tween 20/PBS, pH 7.4 was involved in final incubation of second antibody for 
2 hours at room temperature and then finally washed in the PBS buffer. This 
nitrocellulose paper was developed in chemiluminescence substrate (Section 
2.1.14.2) for 5 minutes and then covered with clingfilm before exposure to X- 
ray film (Section 2.1.14.1).
Staining for protein
The nitrocellulose paper which was blocked with 0.1% Tween 20 in the 
blocking step could be stained with Amido black (Section 2.1.14.3) to identify 
the antigenic bands after developing. Staining was achieved in a 2 minutes 
incubation and destained in 50% methanol, 10% acetic acid in water.
2.2.7.1 Autoradiography
After exposure to X-ray film which was sandwiched between 
nitrocellulose paper and a Dupont "Cronex" intensifier screen in a light proof 
cassette, autoradiographic images were visualised by processing of films in a 
Kodak X-OMAT processor.
2.2.8 Statistical Analysis
Statistical analysis was performed by using the Apple Mac Statworks 
software, and the data was analysed using the Mann-Whitney U test. A p 
value < 0.05 was considered significant. The results were expressed as mean 
± standard deviation.
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3 . The production of monoclonal antibodies reactive with cell 
surface antigens present on human lymph node lymphocytes
3 .1  Aim and summary of study
Previous Mabs identifying putative nodal "homing" markers were 
generated from established tissue culture lines and, in the case of LEU-8, by 
cDNA homology analysis from human to mouse. No other study has set out 
to specifically identify markers unique to the human lymph node as its first aim. 
This chapter describes an approach designed to do this. In order to identify 
marker unique to the node, monoclonal antibodies reactive with nodal T cells 
were generated. Immunisation and screening by FACScan showed that the 
nodal B cells were highly immunodominant and a clone reactive with these was 
isolated and characterised on B and T cell lines. Screening with ELISA on 
"panned" T cells was also then employed and used to isolate monoclonal 
antibodies which were expanded and characterised. Three resultant 
monoclonal antibodies were identified by dual-parameter flow cytometric 
analysis on lymph node lymphocytes, and were compared for reaction with 
peripheral blood lymphocytes.
3 .2  Results
3.2.1 Cell fusion and screening
The procedure for immunisation, fusion, selection of hybrid cells and 
screening of culture were by methods described previously in Section 2.2.1.
Sera of Balb/c mice immunised with a highly enriched population of 
nodal cells were tested by using FACScan or ELISA assay for the appropriate
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fusions (Section 2.2.1.3 and 2.2.1.6.1). Data from serum from a mouse 
immunised with whole lymph node lymphocytes and two sera from mice 
immunised with panned nodal T lymphocytes are shown in Figures 3.1, 3.4, 
3.7a and 3.7b respectively. The mouse immune sera examined all reacted 
with a proportion of nodal lymphocytes. In the case of Figures 3.4 and 3.7b, 
all cells were positive in the node; implying that the serum contained antibodies 
reactive with both T and B cells in the node. The second antibody alone 
sometimes reacted with cells (almost certainly B cells) and sometimes didn’t. 
This may have been because some second antibody supplies were less specific 
so that the anti-mouse IgG antibody reacted with human IgG on human B cell 
surfaces.
Myeloma (SP 2/0) cells were at least over 35% in the S-phase of cell 
cycle (Figures 3.2 and 3.5) on the fusion days.
After fusion, the three clones were cultured according to Section 
2.2.1.5, and the relevant positive clones from the fusion plates were screened 
(Section 2.2.1.6) and selected by FACScan or ELISA assay. SP 2/0 cells 
and spleen cells were used as negative controls, and serum titre was used as 
positive control. Tissue culture supernatant was used as the source of the 
monoclonal antibodies for FACScan and ELISA assay analysis. The results 
are illustrated in Figures 3.3, 3.6 and 3.8. Figure 3.3 showed that more cells 
were positive in the subcloning stage because there were more B cells in the 
node sample used. Figure 3.9 shows the cells of the mouse Balb/c 
hybridoma.
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Figure 3.1 FACScan analysis of serum test from a mouse immunised with 
whole lymph node lymphocytes for the first approach to monoclonal antibody 
production. A represents the histogram of control (2nd antibody only) and B 
shows the histogram of positive serum on nodal lymphocytes.
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Figure 3.2 Analysis of the cell cycle of SP 2/0 cells used for the fusion 
which produced the first monoclonal antibody.
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Figure 3.3 Selection of positive clones from first fusion by FACScan 
analysis. A shows SP 2/0 cell supernatant, B shows spleen cell supernatant, C 
shows the serum control, and D shows the histogram of the selected clone. E 
and F show the selected clone after selection and subcloning (F) compared to 
the control of 2nd antibody only (E).
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Figure 3.4 FACScan analysis of serum test from a mouse immunised with 
panned nodal T cells for the second approach to monoclonal antibody 
production. A represents the histogram of control (2nd antibody only) and B 
shows the histogram of positive serum on nodal lymphocytes.
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Figure 3.5 Analysis of the cell cycle of SP 2/0 cells used for the fusion 
which produced the second monoclonal antibody. S-Phase: 37.7%
A
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Figure 3.6 Selection of positive clones from second fusion by FACScan 
analysis. A shows SP 2/0 cell supernatant, B shows spleen cell supernatant, C 
shows the serum control, and D shows the histogram of the positive clone in 
screening. E represents the histogram of control (2nd antibody only), and F 
shows the histogram of the positive clone in recloning.
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Figure 3.7a Serum test by ELISA assay of plate bound lymph node 
lymphocytes for third monoclonal antibody production strategy.
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Figure 3.7b FACScan analysis of serum test from a mouse immunised with 
panned nodal T cells for the third approach to monoclonal antibody production. 
A represents the histogram of control (2nd antibody only) and B shows the 
histogram of positive serum on nodal lymphocytes.
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Figure 3.8 Selection of positive clone from third fusion by ELISA assay
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3.2.2 Characterisation
Purified IgG Mab labelled with FITC and IgG Mab from tissue culture 
supernatant and ascites fluid as described previously in Section 2.2.1.7 and
2.2.1.8 were prepared and tested by FACScan analysis of antigen binding 
activity. As depicted in Figures 3.10a, 3.10b and 3.10c, the monoclonal 
antibodies reacted with a subset of lymph node lymphocytes. In particular, 
Figure 3.10c shows Mab 3 binding to an antigen more strongly after ethanol 
permeabilisation of lymph node lymphocytes, indicating that it may detect an 
intracellular antigen.
3.2.2.1 Human B cell lines
Three human B cell lines (Raji, Daudi and Ramos) (Section 2.1.17.1) 
were used to investigate the phenotype specificity of Mabs 1, 2, and 3.
Figures 3.1 la, 3.1 lb and 3.1 lc showed that all three reacted with human B cell
lines.
In addition, ELISA assay revealed that Mab 3 also bound to the human 
B cell lines. Figure 3.12 shows the ELISA profile of Mab 3 in tissue culture 
supernatant reacting Raji or Daudi cells.
The epitope recognised by the Mab was analysed on human B cell lines. 
A panel of different cell surface antigens were separated by a preparative 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with 
silver stain as described earlier in Section 2.1.9 (Figure 3.13). Western 
blotting (Figure 3.14) demonstrated that Mab 2 recognised an epitope in 
molecular weight region of the 95 kDa antigen (CD 19) of human B cell lines. 
Mab 1 and 3, however, failed to detect the antigen in Western blotting due to 
high backgrounds.
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3.2.2.2 Reactivity with human T cell line
To investigate the reaction of the Mabs with T cell antigens, the three 
produced Mabs were analysed by using FACScan. Figure 3.15 shows that 
these Mabs did not bind to the human Jurkat T cell line (Section 2.1.17.2).
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Figure 3.10a Characterisation of Mab 1 against lymph node lymphocytes by 
FACScan analysis. A represents the histogram of the control (2nd antibody 
only) and B shows the histogram of the positive clone.
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Figure 3.10b Characterisation of Mab 2 against lymph node lymphocytes 
by FACScan analysis. A represents the histogram of the control (2nd antibody 
only) and B shows the histogram of the positive clone.
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Figure 3.10c Characterisation of Mab 3 against lymph node lymphocytes by 
FACScan analysis. A and C represent the histograms of the control. B and D 
show the histograms of the positive clone. In C and D the cells have been 
permeabilised with ethanol to allow access to intracellular antigens.
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Figure 3.11a Characterisation of Mab 1 on human B cell lines against 
control of 2nd antibody only. (A) Raji cells (B) Daudi cells (C) Ramos cells
159
\
#14iPBK920700SnFL1\F1u
8n CtliTROLItRAJI+Ig G-FITC
rf!j|»14»PBK9Se79ieNn.lsFlu i
IcDAUDI+Ig Q-FITC
'I4»J “LJiV*
#14iPBK9£07006\n_l\Fl 
COHTROLIcRAMOS+Ig G-FITC
Figure 3.11b Characterisation of Mab 2 (ascites) directly FTTC labelled on 
human B cell lines against control of 2nd antibody only. (A) Raji cells (B) 
Daudi cells (C) Ramos cells
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Figure 3.11c Characterisation of Mab 3 (ascites) on human B cell lines 
against control of 2nd antibody only. The cells have been permeabilised with 
ethanol to allow access to intracellular antigens. (A) Raji cells (B) Daudi cells 
(C) Ramos cells
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Figure 3.12 Characterisation of Mab 3 on human B cell lines by ELISA
assay.
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Figure 3.14 Western blotting of monoclonal antibody 2 on cell membrane 
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Figure 3.15 Characterisation of monoclonal antibodies on the Jurkat human 
T cell line. (A) FITC labelled 2nd antibody alone (B) Mab 1 (C) Mab 2 (D) 
Mab 3
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3.2.3 Dual parameter analysis
In order to identify whether the nodal cells identified by the Mabs were 
B or T cells, dual-parameter flow cytometric analysis was performed. All 
cells were stained with Mabs specific for cell surface markers (CD3 and CD 19), 
washed, incubated with the appropriate Mab and detected in a FACScan flow 
cytometer. Figure 3.16 confirmed that all three previously produced Mabs 
identify a B-cell epitope in the lymph node.
3.2.4 Reaction to PBL
Two of the Mabs reacted with peripheral blood lymphocytes as well as 
nodal lymphocytes, but the reactivity of Mabl was not tested in this work. 
Figures 3.17 and 3.18 indicate that the epitope is located in not only LNL but 
also PBL. This result is compared with LEU-8 expression on PBL described 
in Section 4.2.3.
Figure 3.16 Dual parameter analysis of all three monoclonal antibodies on 
lymph node lymphocytes. A left shows anti CD3-PE plus Mab 1-FITC and no 
dual stained cells. A right shows anti CD19-PE plus Mab 1-FITC with most 
cells double stained. B left shows anti CD3-PE plus Mab 2-FITC and no dud 
stained cells. B right shows anti CD19-PE plus Mab 2-FITC with most cells 
double stained. C left shows anti CD3-PE plus Mab 3-FITC and no dual 
stained cells. C right shows anti CD19-PE plus Mab 3-FITC with most cells 
double stained.
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Figure 3.17 Mab 2 (ascites) on PBLs (A) Control (2nd antibody alone)
(B) Mab 2 and 2nd antibody
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Figure 3.18 Mab 3 on PBLs after ethanol fixation (A) Control (2nd
antibody alone) (B) Mab 3 and 2nd antibody
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3 .3  Discussion
A putative nodal homing marker, LEU-8, identified by cDNA homology 
analysis between human and mouse, has been suggested to participate in the 
process of leukocyte extravasation into lymphoid organs. This study was 
designed to identify markers unique to the human lymph node, and to compare 
these with the homing function suggested for the LEU-8 marker (Chapter 4).
Three monoclonal antibodies reacting with nodal cells were screened, 
selected and characterised by flow cytometric analysis and ELISA assay. In 
this study the only way of getting fresh human lymph nodes was during an 
operation for cancer. Post mortem nodes were too necrotic because of the 
time consuming legal formalities involved. The fact that the same Mab didn't 
show the same pattern each time was because a different node was from a 
different patient, and because there were only a few cells in each node and each 
node had a different proportion of B and T cells. The resultant monoclonal 
antibodies reacted with PBL as well as LNL, and bound to B cell lines and 
nodal B cells not the Jurkat T leukaemic cell line and nodal T cells. This was 
surprising as mice were immunised with panned nodal T cells contaminated 
with < 3% B cells. Thus B cells must be very immunodominant The fact 
that all three monoclonal antibodies were to B cells further suggests that within 
the B cells there are particularly immunodominant antigens. In Western 
blotting analysis Mab 2 recognised an epitope in the molecular weight region of 
the CD 19 molecule (95 kDa). It is not surprising that Mabs raised against 
membrane proteins may sometimes fail to detect them on immunoblot. Many 
membrane spanning proteins cross the membrane several times presenting a 
non-contiguous array of conformational epitopes to an external antibody. 
This will be lost on SDS-PAGE. These results indicate that the antigens 
identified were not to the node, but were distributed through out the peripheral
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blood and nodal lymphocytes. This evidence will be compared with LEU-8 
expression on PBL and LNL, and discussed in Chapter 4.
In summary, the monoclonal antibodies produced to date are to B cell 
antigens which are unlikely to be MHC Class I or immunoglobulin. In 
addition, B cells, where not quantitatively dominant in the human lymph node, 
are highly immunodominant. Despite a logical strategy, no specific homing 
molecule was identified. It was therefore of interest to find if other strategies 
had been more successful.
CHAPTER 4
FLOW CYTOMETRIC 
ANALYSIS OF LEU-8 
EXPRESSION ON LYMPH 
NODE AND PERIPHERAL 
BLOOD LYMPHOCYTES OF 
BREAST CANCER PATIENTS
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4 . Flow cytometric analysis of LEU-8 expression on lymph 
node and peripheral blood lymphocytes of breast cancer patients
4.1 Aim of study
The LEU-8 cell surface molecule was previously reported as a human 
homologue of the murine MEL-14 lymph node homing receptor (Section 
1.4.2.2). However, this homing function has not yet been proven in 
humans. If LEU-8 is the lymph node homing receptor there may be expected 
to be more LEU-8+ cells in the nodes than in the blood. This study measured 
the percentage of all T (CD3) and B (CD19) cells in the blood that are also 
LEU-8+ and compared this with the percentage of all CD3+ or CD 19+ cells in 
the nodes that are also LEU-8+ by using dual-colour flow cytometric analysis.
Tumour draining lymph nodes in breast cancer patients represent an 
important site where malignant cells may be recognised by the host immune 
system, eliciting an immune response against the tumour (Whitford et al.y 
1992). The immune response between neighbouring lymph nodes of breast 
cancer patients is variable, and activation of lymphocytes within tumour 
draining lymph nodes may be altered. This work therefore also set out to 
define the contribution of two cell surface antigens, the IL-2 receptor and HLA- 
DR, in the communication between two lymph nodes or blood and nodes in the 
local immune response.
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4 .2  Results
The methodology of lymphocyte staining and gating procedure is 
described in Section 2.2.3.3.I. Sample aliquots were incubated for twenty 
minutes on ice with the relevant monoclonal antibodies (Table 4.1) to specific 
phenotypic and activation markers on the lymphocyte membrane. The validity 
of the gate was checked by the leucogate antibody (Figure 4.la). 5000 events 
were collected for statistical relevance and analysed on the FACScan research 
program. A quadrant was set on the IgG 1 -FITC/IgG2a-PE non-specific 
binding control to include 99.8% of cells for statistical relevance (Figure 4.1b). 
Analysis of lymphocyte subset activation required a dot plot gate to include only 
the positive staining lymphocytes. A histogram was drawn and the X co­
ordinate of the quadrant from the IgG 1 -FlTC/IgG2a-PE non-specific binding 
experiment was used as a marker to measure dual positive cells (Figures 4.8 
and 4.10).
In this study the relative quantitative expression of LEU-8 on CD3/19 
cells and activation markers (CD25 or HLA-DR) on lymphocyte subsets was 
measured on the peripheral blood lymphocytes (PBL) and two types of lymph 
nodes, with one close to the breast cancer tissue (NLN) and one distant (FLN).
4.2.1 LEU-8+ expression on T lymphocyte populations of breast
cancer patients
T lymphocytes expressing the LEU-8 molecule were identified with 
monoclonal anti-LEU 8-F1TC (FL1) and PE labelled monoclonal antibodies 
(FL2) specific for the CD3 cell marker, and percentages were calculated on FL1 
vs FL2 plot (Figures 4.1c, d and e).
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The values obtained for CD3+ LEU-8+ were expressed as a percentage 
of total CD3+ cells. The mean percentages of CD3+ LEU-8+ cells in 
lymphocytes from each analysed source are shown in Table 4.2 : PBL 18.1% 
(range 2.0 - 63.0%), NLN 17.5% (range 0.4 - 85.4%), FLN 13.8% (range 0.3 
- 50.9%). The highest average expression is found in the PBL, whereas the 
NLN shows similar expression pattern to that of PBL and FLN shows a smaller 
value. No statistical significance was observed between the three lymphocyte 
sources (Table 4.4). Within individual patients expression of LEU-8+ CD3+ 
for PBL, NLN and FLN is illustrated in Figure 4.2. The overall expression 
of LEU-8 in the three tissues was very similar with the exception of the one 
among 25 patients with a higher proportion in the near lymph node (Figure 
4.3). Individual patients vary greatly (Figure 4.4).
Figure 4.1 Double stained colour dot plots of LEU-8+ expression on T 
(CD3) cells of a single patient. (A) Control scatter plot. The selected area 
represents the gated lymphocyte populations selected by forward scatter (FSC) 
and side scatter (SSC) parameters. (B) The IgG 1 -FITC/IgG2a-PE level of non­
specific staining in control scatter plot. (C) The Fluorescence 1 (FITC) vs 
Fluorescence 2 (PE) in lymph node lymphocytes. The green area shows the 
FITC labelled LEU-8+ cells. The red area represents the PE labelled CD3+ T 
cells. The yellow populations represents cells expressing both LEU-8+ and 
CD3+. (D) The yellow area represents the LEU-8+ population on T cells in the 
gated histogram. (E) The Fluorescence 1 (FITC) vs Fluorescence 2 (PE) in 
peripheral blood lymphocytes. The yellow area represents the LEU-8+ CD3+ 
cells.
/
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Figure 4.3 Distribution of LEU-8+ on CD3 lymphocyte populations from 
PBL, NLN and FLN of breast cancer patients
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Figure 4.4 Patient variability of LEU-8+ CD3+ expression between the
three lymphocyte sources in breast cancer patients
Table 4.1 Monoclonal antibodies used for flow cytometric analysis of phenotypic 
and activation markers of human lymphocytes
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First antibody Second antibody Function
IgG 1-FITC IgG2a-PE Control
Leucogate
Anti-CD45-FITC Anti-CD 14-PE Control: Differential 
staining of leucocyte 
subpopulations, 
(lymphocytes, monocytes 
and neutrophils)
Anti-CD3-FITC/PE T lymphocytes
Anti-CD 19-FITC/PE B lymphocytes
Anti-Leu 3a-PE Anti-CD25-FTTC IL-2 receptor on CD4+ 
helper T cells
Anti-Leu 2a-PE Anti-CD25-FTTC EL-2 receptor on CD8+ 
cytotoxic T cells
Anti-Leu 3a-PE Anti-HLA DR-F1TC Activated CD4+ helper 
T cells
Anti-Leu 2a-PE Anti-HLA DR-FTTC Activated CD8+
cytotoxic T cells
Anti-Leu 8-FITC Cell surface molecule
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T able 4.2 Comparison of the average percentage of LEU-8+ CD3+ 
expression on blood and lymph nodes
LEU-8 PBL NLN FLN
on CD3 (n=22) (n=25) (n=21)
Minimum 2.0 0.4 0.3
Median 15.9 12.1 10.6
Maximum 63.0 85.4 50.9
Mean 18.1 17.5 13.8
Standard Error 3.6 3.8 2.9
Standard Deviation 16.9 19.1 13.3
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4.2.2 LEU-8+ expression on B lymphocyte populations of breast
cancer patients
B lymphocytes expressing the LEU-8 molecule were identified with 
FITC labelled monoclonal anti-LEU 8 (FLl) and PE labelled monoclonal anti- 
CD 19 (FL2), and percentages were calculated on FLl vs FL2 plot
The expression of LEU-8+ CD 19+ B cells showed a similar trend to 
that of LEU-8+ CD3+ with the mean expression on PBL (38.5%, range 2.3- 
58.4%) being greater than that of NLN (6.8%, range 0.1-17.0%) and FLN 
(10.5%, range 0.5-33.0%) (Table 4.3). The size of the LEU-8+ CD19+ 
population expressed as a percentage of total lymphocytes was not significantly 
different in all tissues (Table 4.4). Individual patient expression within PBL, 
NLN and FLN is illustrated in Figure 4.5. On average there is more LEU-8+ 
expression on B cells in the blood than in both nodes (Figure 4.6). Individual 
patients vary greatly (Figure 4.7).
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Figure 4.7 Patient variability of LEU-8+ CD19+ expression between the
three lymphocyte sources in breast cancer patients
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Table 4.3 Comparison of the average percentage of LEU-8+ CD 19+ 
expression on blood and lymph nodes
LEU-8 PBL NLN FLN
on CD 19 (n=9) (n=15) (n=15)
Minimum 2.3 0.1 0.5
Median 44.2 4.7 4.4
Maximum 58.4 17.0 33.0
Mean 38.5 6.8 10.5
Standard Error 6.5 1.6 3.0
Standard Deviation 19.6 6.1 11.5
Table 4.4 Comparison of LEU-8 expression on lymphocytes from peripheral blood, 
axillary near lymph node and far lymph node of breast cancer patients
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Parameter PBL NLN FLN Statistical
significance
(n=22) (n=25) (n=21)
a. p= N.S.
LEU-8+ CD3+ 18.1 ± 16.9 17.5 ± 19.1 13.8 ± 13.3 b. p= N.S.
c. p= N.S.
(n=9) (n=15) (n=15)
a. p= N.S.
LEU-8+ CD 19+ 38.5 ± 19.6 6.8 ± 6.1 10.5 ± 11.5 b. p= N.S.
c. p= N.S.
Values represent % mean ± standard deviation of lymphocytes expressing the 
LEU-8 cell surface molecule.
(a) is the comparison of PBL and NLN; (b) that of PBL and FLN; (c) that of 
NLN and FLN
Statistical test used: Mann-Whitney U test as the number of unpaired samples
was performed. Statistical significance is taken as a p < 
0.05. (N.S.: Not significant)
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4.2.3 Comparison of LEU-8 expression with that of the antigen 
identified by monoclonal antibodies described in Chapter 3
The antigens on the node identified by the "in house" generated 
monoclonal antibodies were not specific to the node and were distributed 
throught out the peripheral blood and nodal lymphocytes (Chapter 3). 
Similarly, the LEU-8, cell surface antigen previously thought to be involved in 
homing in humans, was expressed in the peripheral blood as well as the lymph 
node of breast cancer patients. These data indicate that the antigen is not 
unique to the human lymph node, and LEU-8 is, from these studies, irrelevant 
to T cell homing and a negative indicator of B cell homing.
4.2.4 Analysis of activation markers
The expression of the activation markers IL-2R (CD25; Tac antigen) and 
HLA DR, both of which undergo upregulation upon antigen stimulation, on 
three lymphocyte populations is summarised in Table 4.5 and 4.6. 
Lymphocytes were gated based on size characteristics.
4.2.4.1 IL-2R (Tac) expression
The expression of the Tac component of the IL-2 receptor was shown to 
be higher on the CD4+ T cells than on the CD8+ T cells in each tissue (Figure 
4.9). The mean percentage of IL-2R expressing CD4+ T cells in NLN 
(23.6%) was higher than in FLN (19.1%), whereas the expression of IL-2R on 
CD8+ T cells showed little change between three lymphocyte populations.
Figure 4.8 A dot plot of dual immunofluorescence of T cells bearing Tac 
(CD25) analysed using quadrant statistics. The upper figure shows the 
analysis gate used to isolate the population expressing the activation marker 
based on the FL-2 channel. The lower figure shows the number of cells from 
the upper 2 quadrants bearing the activation marker based on non-specific FITC 
binding in a control sample containing irrelevant antibody.
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Figure 4.9 Comparison of the Tac (CD25) expression on CD4+ and CD8+
T cells in the peripheral blood, near lymph node and far lymph node
lymphocytes of breast cancer patients
Table 4.5 Comparison of CD25 expression on lymphocytes from peripheral blood, 
axillary near lymph node and far lymph node of breast cancer patients
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Parameter PBL NLN FLN Statistical
significance
(n=16) (n=25) (n=25)
a. p= N.S.
CD4+ CD25+ 25.6 ± 23.7 23.6 ± 14.9 19.1 ± 13.9 b. p= N.S.
c. p= N.S.
(n=17) (n=23) (n=22)
a. p= N.S.
CD8+ CD25+ 14.0 ± 18.0 15.9 ± 14.8 13.0 ± 10.0 b. p= N.S.
c. p= N.S.
Values represent % mean ± standard deviation of lymphocytes expressing 
activation cell marker
(a) is the comparison of PBL and NLN; (b) that of PBL and FLN; (c) that of 
NLN and FLN
Statistical test used: Mann-Whitney U test as the number of unpaired samples
was performed. Statistical significance is taken as ap  <1 
0.05. (N.S.: Not significant)
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4.2A.2 HLA DR expression
As can be seen in Figure 4.11, unlike the CD25 surface antigen the 
HLA DR surface marker was found to be on many more CD8+ T cells from the 
three tissues than CD4+ T lymphocytes. The mean expression of HLA DR 
on CD8+ T cells was found to be greater in the NLN (46.8%) compared with 
the PBL (29.1%) or the FLN (44.0%).
Figure 4.10 A dot plot of dual immunofluorescence of T cells bearing HLA 
DR analysed using quadrant statistics. The upper figure shows the analysis 
gate used to isolate the population expressing the activation marker based on tie 
FL-2 channel. The lower figure shows the number of cells from the upper 2 
quadrants bearing the activation marker based on non-specific LH C binding n 
a control sample containing irrelevant antibody.
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Figure 4.11 Comparison of HLA DR expression on CD4+ and CD8+ T
cells from the three lymphocytes sources in breast cancer patients
Table 4.6 Comparison of the activation status of lymphocytes from peripheral 
blood, axillary near lymph node and far lymph node of breast cancer patients
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Parameter PBL NLN FLN Statistical
significance
(n=16) (n=25) (n=25)
a. p= N.S.
CD4+ HLA-DR 20.5 ± 16.3 30.4 ± 20.5 19.1 ± 13.9 b. p= N.S.
c. p= N.S.
(n=17) (n=24) (n=24)
a. p= N.S.
CD8+ HLA-DR 29.1 ± 22.0 46.8 ± 21.1 44.0 ± 20.2 b. p= N.S.
c. p= N.S.
Values represent % mean ± standard deviation of lymphocytes expressing 
activation cell marker
(a) is the comparison of PBL and NLN; (b) that of PBL and FLN; (c) that of 
NLN and FLN
Statistical test used: Mann-Whitney U test as the number of unpaired samples
was performed. Statistical significance is taken as a p < 
0.05. (N.S.: Not significant)
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4.3 Discussion
Lymphocytes are engaged in constant trafficking from the blood into 
secondary lymphoid tissues, by binding to high endothelial venules (HEV) to 
give maximal efficiency of response. A human peripheral lymph node 
homing receptor fully equivalent in function and expression to the mouse MEL- 
14 antigen has not yet been described and tested because of obvious ethical 
problems. Clearly, the identification of a human peripheral node-specific 
homing receptor is an important goal, both for understanding the physiology of 
human lymphocyte traffic and for its potential clinical diagnostic and therapeutic 
value. The LEU-8 antigen is a human homologue of the murine MEL-14 
molecule, which has been suggested to be to have a homing function, but has 
not to date been tested in humans (Section 1.4.2.2). This study was designed 
to assess the homing function of the LEU-8 molecule by comparison of its 
relative expression in lymph node and peripheral blood of breast cancer patients 
using two-colour flow cytometric analysis. The present data supports the 
view that LEU-8+ CD3+ or CD 19+ cells show no signs of accumulating in the 
node, and indeed the latter show a preference for location in the blood. It is 
clear that lymphocytes do not express LEU-8 preferentially in the node, and 
individual lymph nodes differ greatly. Thus these experiments showed no 
evidence that LEU-8 is a homing receptor. It remains however possible that 
the LEU-8 receptor may be downregulated when the lymphocytes enter the 
node. Andersson et al. (1994) have claimed that a number of cell adhesion 
molecules, including VLA-4, LFA-1 and ICAM-1 are up-regulated on CD8+ 
cells, whereas the lymph node homing receptor MEL-14 is down-regulated 
(Kishimoto et al.t 1990; Stibenz and Buhrer, 1994) during systemic virus 
infection. In this context the human lymph node homing receptor CD44 
(Chapter 5) is up-regulated (Lynch et al., 1989) to operate successively in 
controlling extravasation, and has its special role in the interaction between 
lymphocyte and endothelium. It should be noted that, in this study, the CD44
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receptor was expressed in a higher percentage of cells in lymph nodes than in 
peripheral blood (Chapter 5). This is of interest because decreased expression 
of MEL-14 is linked to up-regulation of CD44. Thus, there was no functional 
evidence from this study that the LEU-8 cDNA homologous to mouse MEL-14 
antigen does indeed encode a human lymph node homing receptor.
The immune response within human breast cancer patients is highly 
variable and may be influenced not only by the immunological status of the 
patient but also by the oncogene complement of the tumour. Breast cancer 
patients show a substantial locoregional immune response within the axillary 
lymph nodes. These lymph nodes in breast cancer patients represent an 
important site, where malignant cells may be recognised by the host-mediated 
immune system draining the breast primarily. Alam et al. (1993) reported that 
the percentage of CD8+ T cells expressing HLA DR and IL-2 receptors (Tac) 
was significantly higher in invaded nodes and, while CD4+ T cells expressing 
HLA DR were also in a higher proportion in invaded nodes, the difference in 
the proportion of Tac expressing CD4+ T cells failed to reach significance 
within the same stage II patients. These results suggest that the presence of 
metastatic tumour cells in a lymph node has an effect on the specific alterations 
of the lymphocyte subpopulations. In consequence, the general activation 
state of the lymphocytes in the nodes may be altered. As such, the 
comparison is likely to be most relevant between two axillary lymph nodes or 
between peripheral blood and lymph nodes. In this study the activation 
marker IL-2 receptor (Tac) was present on a higher proportion on CD4+ than 
CD8+ lymphocytes from all three sources. In contrast, the percentage of 
CD8+ T cells bearing HLA DR was higher than that of CD4+ T cells in all 
cases. This activation marker was also found to be expressed on higher 
numbers of CD4+ and CD8+ T cells in near lymph nodes than in peripheral
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blood from matched pairs of the same stage I patients. It is not known 
whether this reflects any functional difference in the expression of the markers 
on these T cell subsets. IL-2 receptor and HLA DR as activation markers, 
however, should be interpreted with caution. An increased expression of the 
activation markers indicate an activated state, but these may subsequently 
undergo down-regulation following binding of the relevant ligand.
CHAPTER 5
CD44 AND LEU-8 
EXPRESSION ON 
LYMPHOCYTES AND 
TUMOUR CELLS FROM 
BREAST CANCER PATIENTS
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5 . CD44 and LEU-8 expression on lymphocytes and tumour
cells from breast cancer patients
5 .1  Aim of study
The human CD44 cell surface glycoprotein is a polymorphic molecule 
found on a wide variety of different tissues. CD44, which has been 
implicated in lymphocyte homing, tumour metastasis, T cell activation and 
extracellular matrix attachment, consists of a large number of related isoforms 
that derive from the differential splicing of a single CD44 gene transcript. 
Different CD44 isoforms may be present in the serum of cancer patients and 
serum CD44 concentrations may be an indicator of tumour metastasis in patients 
with malignant diseases (Guo et al., 1994). This study was designed to 
investigate whether CD44 has a homing function in breast cancer patients. If
CD44 is the lymph node homing receptor there may be more CD44+ cells in the 
nodes than in the blood of breast cancer patients. The percentage of all 
lymphocytes in the blood expressing CD44+ was measured by flow cytometric 
analysis, and was compared with the percentage of all lymphocytes in the nodes 
that are also CD44+. This work additionally asked whether tumour cells 
carry CD44 or LEU 8 and, if so, whether the expression on primary tumour 
was lower or higher than on metastatic tumour in the node.
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5 .2  Results
5.2.1 CD 44+ expression on lymphocyte populations of breast cancer
patients
The lymphocytes expressing the CD44 molecule were identified with 
monoclonal anti-CD44-HTC (FL1), and percentages were calculated on the 
FL1 vs FL2 plot. The results obtained for CD44+ expression on 
lymphocytes are illustrated in Figure 5.1. There were no significant trends 
observed between three lymphocyte sources of breast cancer patients (Table 
5.1), but differences were noted. While the mean percentage of CD44+ cells 
in NLN was higher (84.5%; range 36.3 - 99.0%) than that of CD44+ in PBL 
(71.7%; range 0.1 - 98.9%), the mean percentage of CD44+ cells in FLN 
(86.1%; range 45.2 - 94.0%) showed a similar pattern to that of CD44+ on 
NLN (Table 5.2). The overall percentage of CD44+ cells in the three tissues 
is shown in Figure 5.2. Although the expression of CD44 on PBL had a 
similiar average to other two groups, the distribution was broader. In 8/10 
patients virtually all lymphocytes in the node were CD44+ whereas this is only 
the case for 9/16 PBL samples. Individual patients showed a large variability, 
with some cases of higher percentages on PBL and others with the reverse 
(Figure 5.3).
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Figure 5.1 Percentage of CD44+ expression within the total gated
lymphocyte populations of breast cancer patients
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Figure 5.3 Patient variability of CD44+ expression between the three
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Table 5.1 Comparison of % of CD44+ lymphocytes in peripheral blood, 
axillary near lymph node and far lymph node of breast cancer patients
CD44 PBL
(n=16)
NLN
(n=10)
FLN
(n=10)
Statistical
significance
a. p= N.S.
71.7 ± 33.4 84.5 ± 24.1 86.1 ± 20.0 b. p= N.S.
c. p= N.S.
Values represent % mean ± standard deviation of lymphocytes expressing 
CD44 cell surface molecule.
(a) is the comparison of PBL and NLN; (b) that of PBL and FLN; (c) that of 
NLN and FLN
Statistical test used: Mann-Whitney U test as the number of unpaired samples
was performed. Statistical significance is taken as a p < 
0.05. (N.S. : Not significant)
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Table 5.2 Comparison of the average percentage of CD44+ expressing cells 
within the three lymphocyte populations of breast cancer patients
CD44 PBL NLN FLN
(n=16) (n=10) (n=10)
Minimum 0.1 36.3 45.2
Median 90.3 95.9 94.0
Maximum 98.9 99.0 94.0
Mean 71.7 84.5 86.0
Standard Error 8.4 7.6 6.3
Standard Deviation 33.4 24.1 19.9
206
5.2.2 Comparison of CD44+ and LEU-8+ expressing cells in PBL of
breast cancer patients
The mean percentage of CD44+ cells (72.1 ± 30.3%) was almost two­
fold higher than the mean percentage of LEU-8+ cells (41.3 ± 9.2%) in 
matched patient samples. Only 2/12 patients showed lower CD44 expression 
than LEU-8 expression. Frequencies of cells expressing these two antigens 
in peripheral blood are shown in Figure 5.4.
% 
CD
44
+ 
an
d 
LE
U-
8+
 
ce
lls
207
100 -
8 0 "
6 0 -
4 0  -
2 0 -
L E U - 8C D 4 4
Cell surface molecules on peripheral blood
Figure 5.4 Comparison of percentage CD44+ and LEU-8+ expressing cells
in peripheral blood lymphocytes of 12 samples from breast cancer patients
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5.2.3 Metastasis pattern of CD44 and LEU-8 on tumour cells from 
breast cancer patients
Expression of CD44 and LEU-8 on the primary tumour and metastatic 
tumour invaded lymph nodes of breast cancer patients was determined utilising 
flow cytometric analysis. The low invaded draining axillary nodes are as 
close as 5cm to the tumour, and the high tumour free ones are often 15-20cm 
away (Figure 1.13). Figure 5.5 shows a scatter plot which excluded the 
lymphocytes from the analysis. There was a mean percentage of 56.1 ± 
27.6% CD44+ in primary tumour cells and 58.0 ± 19.5% in metastatic tumour 
cells. This difference was not statistically significant (p=0.89) (Figure 5.6). 
LEU-8+ was also higher in metastatic tumour cells, being 41.3 ± 25.2% 
compared to the primary tumour value of 33.9 ± 15.2%. This change was 
also not statistically relevant (p=0.44) (Figure 5.7).
5.2.4 Expression of CD44 and LEU-8 within regional tumour draining 
lymph nodes
Expression of CD44 in the lymphocytes of tumour invaded or 
uninvaded lymph nodes was compared with that of LEU-8. The overall 
expression of CD44 and LEU-8 in the tumour invaded lymph nodes is 
illustrated in Figure 5.8. The mean expression of CD44 in the 11 tumour 
invaded lymph nodes was found to be greater (64.7 ± 35.8%) than that of 
LEU-8 (19.2 ± 12.9%) reaching statistical significance p=0.005. The mean 
percentage of CD44 expression was higher in the 5 uninvaded lymph nodes 
(35.4 ± 22.0%) than that of LEU-8 (13.4 ± 7.4%) although this failed to reach 
statistical significance (p=0.139) (Figure 5.9). The mean percentage of 
expression of CD44 in the 5 invaded lymph nodes (35.5 ± 26.7%) was similiar 
to the uninvaded lymph nodes (35.4 ± 22.0%), however this trend was not
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statistically relevant (p=0.993) (Figure 5.10). Higher mean expression of 
LEU-8 was noted in the 5 invaded lymph nodes (20.9 ± 4.6%) than in the 
uninvaded lymph nodes (13.4 ± 7.4%) the trend failing to make statistical 
significance (p=0.179) (Figure 5.11).
Figure 5.5 Scatter plot of tumour gate. The selected area represents the 
gated tumour populations by forward scatter (FSC) and side scatter (SSC) 
parameters. Lymphocytes fall in the lower, excluded part of the plot.
% 
CD
44
+ 
C
el
ls
211
100
8 0 -
6 0 -
4 0 -
2 0 -
1 2
Tumour
Figure 5.6 The comparison of % CD44+ cells between (1) metastasis in 
node and (2) primary tumour of matched samples from 6 breast cancer patients
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Figure 5.7 The comparison of % LEU-8+ cells between (1) metastasis in 
node and (2) primary tumour of matched samples from 6 breast cancer patients
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5 .3  D iscussion
Axillary lymph nodes in breast cancer patients are ideally situated to 
encounter tumour antigen and mediate immune responses to tumours. At the 
same time, metastases/tumour invaded nodes influence the lymphocytes within 
such nodes and determine the tumour-host interaction. This section was 
designed to study two main hypotheses, (a) the potential homing function of 
CD44 and (b) the potential involvement of cell surface glycoproteins, CD44 and 
LEU-8, in cancer metastasis. Expression of CD44 and LEU-8 on 
lymphocytes from breast cancer patients was defined by flow cytometric 
analysis using monoclonal antibodies to cell surface markers. Furthermore, 
two groups of nodes, tumour-free and tumour invaded lymph nodes, from the 
same patients were compared.
In general, CD44+ cells were preferentially located in the node. 
However the percentage of CD44+ cells was so high on most human 
lymphocytes, and there was so little difference between lymph node and 
peripheral blood that it was difficult to deduce evidence of homing . On the 
other hand, an interesting feature in this study was that there were more cells 
expressing CD44 than LEU-8 in the peripheral blood. This suggests that 
CD44 might be a homing receptor in humans, but more data is required before 
statistical analysis may have validity
An analysis of CD44 and LEU-8 expression on lymphocyte populations 
from local lymph nodes and tumours showed correlation with metastatic cells, 
and may indicate important elements in the metastatic process. Although the 
mean percentage of CD44 expressing cells was higher than the mean of 
percentage of LEU-8 expressing cells in primary tumour and axillary nodal 
metastases, CD44 and LEU-8 were not significantly different in the tissues of 
patients studied. The observations showed that tumour cells in both primary 
and metastatic tumours express CD44. More interestingly they also express
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substantial amounts of LEU-8 which is generally described as a lymphocyte 
marker. This result provides evidence that CD44 and LEU-8 cell surface 
molecules may be involved in tumour metastasis. Jackson et al. (1993) 
observed that many tumour types do not express CD44 and that CD44 may 
therefore not be a tumour-specific marker for malignant disease in all cases. 
Taken together, the results of this study suggest that cell surface adhesion 
molecule CD44 may be involved in the lymphatic spread of tumour cells, 
possibly by mimicking circulating lymphocytes, and measurement of the CD44 
and LEU-8 may have prognostic and diagnostic potential in primary and 
metastatic breast carcinomas. However the patient number is too small for 
any firm conclusion to be drawn.
CHAPTER 6 
GENERAL DISCUSSION
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6 . General Discussion
This study was initiated to investigate whether the putative human 
lymph node homing receptors (LEU-8 and CD44) have an obvious homing 
function in humans by comparison of their relative expression in lymph nodes 
and peripheral blood of breast cancer patients using dual-colour flow cytometry. 
For the work described in this thesis tumours, blood and tumour draining 
lymph nodes of breast cancer patients were obtained from Department of 
Surgery, Western Infirmary, Glasgow. The experimental procedure in 
Chapter 3 was designed to generate antibodies against human lymph node cells 
in order to determine whether they contained a marker reactive with lymph 
nodes. At the same time, these antigens were compared with the homing 
function suggested for the LEU-8 marker (Chapter 4). Chapter 5 analysed 
whether CD44 has a homing function and investigated the metastasis pattern in 
both primary tumours and tumour-un/invaded nodes of breast cancer patients. 
Additionally, it asked whether tumour cells carrying CD44 and LEU-8 show 
lower or higher expression on primary or metastatic tumours. This work also 
defined the contribution of both phenotypic markers (CD4 and CD8) and 
activation markers (IL-2 receptor and HLA-DR) in the communication between 
two lymph nodes (near and far from their draining tissue) or blood and nodes in 
the local immune response (Chapter 4).
6.1  Flow cytometry
The flow cytometer used throughout this research was a FACScan 
(Becton Dickinson, Ltd., U.K.). This instrument performs DNA analysis 
(Chapter 3), preferential screening of individual cell populations (Chapter 3), 
analysis of phenotypic and activation status (Chapter 4) and has many clinical 
research applications (Chapter 4 and 5). Flow cytometry is an excellent tool
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for analysing the expression of cell surface antigens of tumour cells and/or 
lymphocytes with the ability of discriminating live from dead cells that will 
increase accuracy of data analysis. Cells bearing the specific markers were 
simultaneously identified in one sample using combinations of two different 
monoclonal antibodies conjugated to different fluorochromes (FlTC/PE). The 
number of cells analysed can be as high as 50,000 for each sample in a 
relatively short space of time. Within the five-parameters (three fluorescence 
channels, forward scatter, FSC and side scatter; SSC), it is possible to select for 
defined populations, and gate out tumour cells from the associated lymphocyte 
population. However, both selection and gating of a particular cell population 
from an irrelevant one depend on personal judgement This can lead to an 
element of inaccuracy in the quantitative analysis of the data in every case. 
Tumour cells and lymphocytes were tested (5000 cells/run) for CD44/LEU-8 
expression by flow cytometry. The appropriate negative controls establishing 
background fluorescence and non-specific staining by the primary and 
secondary antibodies were employed. Means and standard deviations of 
LEU-8/CD44 surface fluorescence values were calculated.
6 .2  Production of monoclonal antibodies to LNLs
The methodology of MAb generation has developed with rapid progress 
from polyclonal animal antibodies, rodent monoclonal antibodies and now 
humanised antibodies during over the past 20 years. For the generation of 
good monoclonal antibodies, the SP2/0 myeloma cell line carried as tumour 
from the Balb/c mouse was fused in PEG with the spleen cells from a hyper 
immune mouse.
There has been no previous study on any antibody generated against the 
lymphocytes from human lymph nodes for identification of unique markers.
222
Three clones were produced in this study, all using separate immunisation 
schedules, of which one clone was from a mouse immunised with whole lymph 
node lymphocytes and two clones from mice immunised with panned nodal T 
cells contaminated with <3% B cells. The positive clones selected were 
analysed either by ELISA or by FACScan. The MAbs did not show the same 
reactivity pattern each time because a different node was from a different 
patient, and because there were only a few cells in each node and each node had 
a different proportion of B and T cells. Three resultant MAbs reacted with 
lymph node as well as peripheral blood lymphocytes, and this result indicated 
that the antigens defined were distributed through out the peripheral blood and 
lymph node lymphocytes. In Western blot analysis, however, MAb 1 and 3 
failed to detect antigen, while MAb 2 recognised an epitope in the molecular 
weight region suggested as CD19 B cell marker (95 KDa). Dual-colour flow 
cytometry analysis also showed that the B cells must be very highly 
immunodominant in the human lymph node despite immunisation with >97% T 
cells. All MAbs also bound to B cell lines and nodal B cells not T cell lines 
and nodal T cells. Taken together, the epitope recognised by the MAbs was 
on human B cells, and is unlikely to be MHCI or immunoglobulin. Finally, 
the antigens identified were not specific to the node, and this result suggests that 
LEU-8 molecule has no homing function in human lymph nodes (Chapter 4).
6 .3  Analysis of established lymph node homing receptor
antigens
Over the past decade, the interaction between leukocytes and 
endothelium has been suggested to be of extreme importance in the 
communication of the elements of the immune system because of the discovery 
of various adhesion molecules expressed during early formation and 
differentiation of the elements in the bone marrow, the thymus or at other
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peripheral sites. In addition, these adhesion molecules are thought to play an 
important role in antigen-driven activation of lymphocytes, and in the guiding 
and retaining of the cells on the extracellular matrix components within 
lymphoid organs and connective tissue. As a result of the multitude of
adhesion molecules involved in the adhesion and extravasation of leukocytes to 
endothelium, many therapeutic approaches are based on the reaction of MAbs 
against adhesion molecules or structural parts of the ligands. Lymphocyte 
interactions with high endothelial venules (HEV) also involve very similar 
sequential rolling, activation, and activation-dependent sticking events. In 
final step (diapedesis), the recruitment of leukocyte from the blood into sites of 
inflammation or into lymphoid tissues requires the presence of specific 
chemoattractant gradients and appropriate substrates for leukocyte migration.
In considering this model, L-selectin functions as a dominant 
lymphocyte homing receptor in lymphocyte trafficking to distinct sites, whose 
HEV express high levels of the peripheral node addressin/ligand for the L- 
selectin. In addition, CD44 may also be involved in lymphocyte homing, 
immune function, and tumour metastasis. In certain conditions, it may be
desirable to inhibit particular lymphocyte or leukocyte homing interactions as 
selectively as possible, and they represent an attractive target for suppression of 
inflammation in chronic inflammatory diseases and other immune-mediated 
pathologies. Clearly, the important goal of this research of lymphocyte 
trafficking is both for understanding of physiology of immune mechanism and 
for its potential clinical diagnostic and therapeutic value; of course, in relatively 
acute clinical syndromes, the selectivity of the therapy may be less important 
than its overall effectiveness.
In this research, a major problem in the analysis of LEU-8 or CD44 
expression was a variability of samples between patients. The reasons for 
variability are mainly physiological and technical. The only way of getting
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fresh human lymph nodes, tumours and blood was during an operation for 
cancer. Thus the cells were obtained at one single time point. Post mortem 
samples were too necrotic because of the time consuming legal formalities 
involved. The physiological factors in each patient, for example, the 
difference in age, or whether pre-menopausal may affect the cellular 
composition. Infection with opportunistic pathogens which activate the 
immune system also can affect the expression of a number of phenotypic and 
activation markers. Additionally, genetic variation can involve the protein 
synthesis mechanism of cell surface markers. On the other hand, expression 
may be lost during the handling of samples in the laboratory, in the steps of 
thawing the frozen cell suspension after long storage in liquid nitrogen, and in 
subsequent washing. Although the samples used in this research did not have 
the optimum conditions for analysis, the relative comparison of LEU-8 or CD44 
expression on samples gave an indication of the conclusions which might be 
obtained using a larger sample.
The Mann-Whitney test used for the comparison of the difference in the 
medians of the two independent groups did not show statistical validity, 
because the numbers of samples in each group was small (Chapter 5).
6 .3 .1  LEU-8
A few papers have reported that the LEU-8 marker is human homologue 
of the Mel-14, L-Selectin, as previously mentioned (Section 1.4.2.2). The 
putative human nodal "homing" marker LEU-8 by cDNA homology analysis 
from human to mouse has not been proven in humans because of obvious 
ethical problems. This study was designed to assess the homing function of 
LEU-8 marker using measurement of the relative expression of LEU-8+ 
populations on human axillary lymph node and peripheral blood of breast
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cancer patients by dual-colour flow cytometry. However, there was no 
indication that CD3+ or CD 19+ cells express LEU-8 preferentially in the node, 
and individual lymph nodes differ greatly. Moreover, no specific nodal
antigen for homing was identified (Chapter 3). Thus, this work showed that, 
although LEU-8 cDNA has some homology to Mel-14 DNA, the encoded 
proteins have different biological functions. More interestingly, the LEU-8 
cell surface molecule may be involved in tumour metastasis (Chapter 5).
6 .3 .2  CD 44
The integral membrane glycoprotein CD44 is expressed on a variety of 
cell types including peripheral blood leukocytes (B and T lymphocytes, 
monocytes and granulocytes) and red cells. It is also weakly expressed on 
platelets, and in soluble form in plasma. CD44 has long been known to be 
involved in the interaction of lymphocytes and endothelium via interaction with 
extracellular matrix components such as hyaluronic acid. The CD44 molecule 
mediates a variety of functions: leukocyte-endothelial cell binding, lymphocyte 
homing, extracellular matrix binding, enhancement of T cell activation and 
adhesion to monocytes (Section 1.4.2.3). The finding of splice variants also 
showed that these molecules are associated with aberrant migration and 
metastasis (Section 1.4.3). Although quantitative and qualitative changes in 
CD44 can be used to discriminate primary tumours from corresponding normal 
tissue in a number of system, there is no consensus as to the role of CD44 in 
the progression of tumours.
In this experiment, monoclonal anti-human CD44 (mouse IgGl isotype) 
derived from the clone A3D8 recognising an epitope on both standard and 
variant forms of CD44, was used to define its homing function and metastasis 
pattern. This study suggestes that CD44 marker might be a homing receptor
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in humans although the validity of the statistical analysis was limited by small 
sample number. The CD44 molecule was also expressed in the primary 
tumour and the axillary metastatic lymph node.
6 .4  Local immunological response in human lymph nodes
In breast cancer patients, tumour draining lymph nodes represent an 
important site where malignant cells may be recognised by eliciting a host 
immune response to the tumour. The axillary lymph node metastasis of breast 
cancer patients is currently the important prognostic clinical indicator. The 
lymphocyte subpopulations in regional lymph node and peripheral blood of 
early breast cancer patients were analysed according to their distance from the 
primary tumour. In this study, the comparison was likely to be most relevant 
between two axillary lymph nodes or between peripheral blood and lymph 
nodes from the same patient While the IL-2 receptor was present on a higher 
proportion on CD4+ than CD8+ cells, the percentage of CD8+ cells bearing 
HLA-DR was higher than that of CD4+ cells in all three sources. This 
activation marker was also found to be expressed on higher numbers of CD4+ 
and CD8+ T cells in near lymph nodes than in peripheral blood, and in near 
than far lymph node. This general activation of the lymph node is reflected in 
the specific alterations of the lymphocyte subpopulations. The alteration in 
local immunocompetent cell subsets may represent essential elements in the 
activated state of regional lymph node and in the progression of the cancer.
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6 .5  Conclusions
In the human lymph node, B lymphocytes were highly 
immunodominant, not quantitatively dominant. This research showed that the
suggested LEU-8 marker has no homing function in humans, and CD44 might 
be a human lymph node homing receptor. Both CD44 and LEU-8 may have 
prognostic and diagnostic potential in primary and metastatic breast carcinomas. 
The local regional lymph nodes of breast cancer patients show a specific 
alteration of lymphocyte subpopulations and activation status. Finally, it may 
be noted that there were trends of variability in the results obtained from this 
study.
In further work, human nodal antigen should be identified using, 
possibly, a protein sequencing technique, and more samples are required for 
any firm conclusion to be drawn with greater statistical validity.
CHAPTER 7 
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